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Abstract 
Myotonic dystrophy type 1 (DM1) is a rare disease characterized by 
muscular defects, as well as, cognitive and mood alterations. Although 
these neurophysiological disturbances are very debilitating, there is lack of 
data on the neurobiological mechanisms involved, and no specific treatment 
is available. Here, we investigated the neurobiological correlates 
underlying MBNL2 loss-of-function using two transgenic mouse lines: (i) 
constitutive Mbnl2 knockout (KO) mice and (ii) tissue-specific KO mice, 
where Mbnl2 expression is selectively deleted in the glutamatergic neurons 
of the forebrain. We demonstrated that both models exhibit long-term 
memory recognition deficits and a depressive-like state associated with 
increased microglia and altered neurochemical levels. Moreover, chronic 
treatments with the psychostimulant methylphenidate and the atypical 
antidepressant mirtazapine attenuated these behavioural alterations through 
a reduction of pro-inflammatory microglial overexpression and restoring 
the levels of several neurotransmitters and its receptors. Together, these 
data reveal new insights into the neurobiology of DM1 and provide 
evidence that methylphenidate and mirtazapine could be novel potential 
candidates to alleviate the debilitating symptoms related to the central 
nervous system in patients with DM1. 
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Resumen 
La distrofia miotónica tipo 1 (DM1) es una enfermedad rara caracterizada 
por defectos musculares, así como por alteraciones cognitivas y afectivas. 
Aunque estas alteraciones neurofisiológicas son muy debilitantes, faltan 
datos sobre los mecanismos neurobiológicos involucrados, y no hay un 
tratamiento específico disponible. Aquí, investigamos los correlatos 
neurobiológicos subyacentes a la pérdida de función de MBNL2 utilizando 
dos líneas de ratones transgénicos: (i) ratones knockout (KO) constitutivos 
del gen Mbnl2 y (ii) ratones KO condicionales con una deleción específia 
del gen Mbnl2 en las neuronas glutamatérgicas del cerebro anterior. Los 
resultados demostraron que ambos modelos exhiben déficits de 
reconocimiento de memoria a largo plazo y un estado depresivo, asociado 
con un aumento de la microglia y niveles neuroquímicos alterados. 
Además, los tratamientos crónicos con el psicoestimulante metilfenidato y 
el antidepresivo atípico mirtazapina, atenuaron estas alteraciones del 
comportamiento mediante una reducción de la sobreexpresión microglial 
proinflamatoria y el restablecimiento de los niveles de varios 
neurotransmisores y sus receptores. Juntos, estos datos aportan nuevos 
conocimientos sobre la neurobiología de DM1 y proporcionan evidencia de 
que el metilfenidato y la mirtazapina podrían ser nuevos candidatos 
potenciales para aliviar los síntomas debilitantes relacionados con el 
sistema nervioso central en pacientes con DM1. 
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1. Overview of Myotonic Dystrophy 
Myotonic dystrophy (dystrophia myotonica, DM) is an autosomal 
dominant disorder with a progressive multisystemic phenotype. DM is 
primarily characterized by muscle weakness and myotonia, but also by an 
extra-muscular involvement including cardiac arrhythmias, insulin 
resistance and central nervous system (CNS) abnormalities. Based on the 
genetic alterations, DM is classified in two main forms: (i) myotonic 
dystrophy type 1 (DM1) also known as Steinert’s disease, caused by 
increased CTG (cytosine-thymine-guanine) expanded (CTGexp) repeats in 
the 3’ untranslated region (UTR) of the dystrophia myotonica protein 
kinase (DMPK) gene on chromosome 19q13.3 (Brook et al., 1992) and (ii) 
myotonic dystrophy type 2 (DM2), a milder form, resulting from a CCTG 
intronic expansion in the zinc finger protein 9 (ZNF9) gene, also known as 
CNBP on chromosome 3q21.3 (Figure 1) (Liquori et al., 2001). At the 
molecular level, when these genes are transcribed, pathogenic transcripts 
are formed (CUGexp or CCUGexp) which are retained in the nuclei of cells 
as ribonuclear aggregates, named foci. These aggregates in hairpin loop 
structures disrupt several RNA-binding proteins (RBPs) such as the 
muscleblind-like (MBNL) family, which normally regulate the alternative 
splicing transition from fetal to adult isoforms (Lee and Cooper, 2009).  
 
Strong evidence supports that RNA toxicity plays a major role in disease 
pathology due to microsatellite expansions in noncoding regions that can 
be transcribed into pathogenic transcripts, modifying the bioavailability of 
splicing factors, altering the alternative splicing processes and enhancing 
fetal mRNA isoforms. Thus, dysfunctional or inappropriate protein 
expression patterns with deleterious effects on adult tissues contribute to 
the pathogenesis of DM1 (Sznajder and Swanson, 2019).  
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Figure 1. Genes involved in myotonic dystrophy type 1 (DM1) and type 2 
(DM2).  On the top, the location of CTG repeats (DM1) in the 3’ untranslated 
region (UTR) of the DMPK gene. On the bottom, the location of CCTG repeats 
(DM2) in the intron 1 of the ZNF9 gene. (Blue boxes represent exons). 
 
 
DM1 symptoms often include myotonia, muscle weakness and wasting, 
along with cognitive deficits with impairments in attention, memory, 
visuospatial and executive functions (Rubinsztein et al., 1997; Meola and 
Sansone, 2007; Minnerop et al., 2011; Gallais et al., 2017). Moreover, 
longitudinal studies have reported many debilitating neuropsychological 
symptoms with excessive daytime sleepiness, cognitive decline, 
depression, anxiety and apathy (Thornton, 2014; Minier et al., 2018).  
 
Although these data highlight the multitude of incapacitating symptoms in 
patients with DM1 (Laberge et al., 2009; Heatwole et al., 2012), to date 
there is no effective treatment for the muscular or the neurological 
alterations observed in DM1 (Ashizawa and Sarkar, 2011; Udd and Krahe, 
2012; Thornton, 2014).  
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2. Genetics of Myotonic Dystrophy type 1 (DM1) 
Despite being a rare disease, DM1 is the most common form of muscular 
dystrophy in adulthood with a worldwide prevalence of 1 in 8000 people 
(Harper et al., 2001; Lee and Cooper, 2009; Suominen et al., 2011). DM1 
belongs to a group of disorders called microsatellite expansion disorders. 
Microsatellite repeats are short repeat sequences of 2-10 nucleotides with 
variable sizes among normal individuals and have important roles in 
genome evolution. So far, more than 40 neurological disorders are caused 
by microsatellite repeat expansions including Huntington disease, fragile 
X syndrome, DM1 and DM2, and amyotrophic lateral sclerosis (Pearson 
et al., 2005; Batra et al., 2010; La Spada and Ranum, 2010; Rohilla and 
Gagnon, 2017). 
 
These microsatellite pathologies lead to defects in the alternative splicing 
of many primary transcript precursors or messenger RNA (mRNA). 
Alternative splicing is a regulated process by which functional mRNA can 
be generated through multiple isoforms of a single pre-mRNA. During this 
gene expression process, the introns are spliced out and exons can be 
merged in different mRNA variants generating many protein isoforms. 
During mammalian development, these splicing events are necessary for 
different biological processes and play a critical role in the remodelling of 
tissues in different developmental stages and throughout lifetime 
(Blencowe, 2006; Kalsotra and Cooper, 2011; Irimia and Blencowe, 2012). 
In DM1 tissues, the normal developmental splicing pattern is disrupted, 
resulting in the expression of fetal protein isoforms in adult tissues (Figure 
2).  
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Figure 2. Schematic representation of spliceopathy in myotonic dystrophy 
type 1. Expanded CTG (CTGexp) repeats in DNA leads to toxic RNA transcripts 
forming hairpin-like structures that sequester RNA-binding factors. This 
sequestration in nuclear foci prevents the normal processing of pre-mRNAs by the 
RNA-binding factors. They can not switch to an adult pattern resulting in aberrant 
alternative splicing inducing fetal-like splicing patterns (Adapted from Martí and 
Estivill, 2013).  
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2.1. Genotype-Phenotype correlation 
In the general population, healthy people with normal DMPK alleles have 
5 to 35 CTGexp repeats. DM1 patients with the pre-mutation allele comprise 
ranges between 35 to 50 triplet repeats, which are asymptomatic but have 
a higher risk of having children with larger expanded repeats (Martorell et 
al., 2001). In DM1 patients, CTGexp repeats greater than 50 have been 
associated with disease manifestations. Once in the range of disease, the 
clinical phenotype is highly variable, but in general, larger expanded 
repeats are mostly associated with an earlier age of onset and more severe 
symptoms (Harley et al., 1993; Logigian et al., 2004), while smaller 
pathological repeats are often correlated with a milder phenotype 
(Arsenault et al., 2006). Therefore, disease severity correlates with repeat 
size, and is inversely proportional to the age of onset of symptoms. (Figure 
3). DM1 phenotypes can be classified as congenital, childhood- or 
juvenile-onset, adult- and late-onset (see section 3). 
 
Figure 3. Genotype-phenotype correlations in patients with DM1. Larger CTG 
repeats (in green) are correlated with an earlier age of onset (in orange) and more 
severe symptoms (in blue). On the left range, CTG repeat length greater than 1000 
appears at birth with the congenital form. By contrast, in the range on the right, 
CTG repeats around 50 are related to the late phenotype that usually appears after 
40 years of age. 
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2.2. Somatic instability and genetic anticipation  
Pathological mutations in DM1 occur at high frequency in both germline 
and somatic cells (Brouwer et al., 2009). This is because expanded CTG 
repeats are very unstable (Pearson et al., 2005; Meola and Cardani, 2015). 
As a result of this instability, a single individual may have different repeat 
sizes in cells and tissues, called somatic mosaicism. This somatic 
mosaicism is age-dependent and tissue-specific, and a likely contributor to 
the progressive nature of DM1 symptoms (Morales et al., 2012). Notably, 
the repeat length is always much larger in muscle DNA than that observed 
in blood (Thornton et al., 1994; Monckton et al., 1995). As disease 
symptoms are most prominent in post-mitotic tissues such as skeletal 
muscle, heart and brain, it is thought that an abnormal DNA repair 
mechanism may be responsible for repeat instability (Dion, 2014). 
 
It is also important to note that the expanded CTG repeats in DM1 increase 
in size from generation to generation, leading to a dramatic 
intergenerational instability. This is due to expansions in germ lines giving 
rise to the phenomenon called “genetic anticipation”, which is the 
occurrence of an increase disease severity, and an earlier age of onset in 
successive generations due to an increase in repeat length during parent-
to-child transmission (Figure 4). Thus, offspring of a parent with DM1 may 
inherit longer repeats than those present in the transmitting parent.   
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Figure 4. Family pedigree pattern of myotonic dystrophy type 1 (DM1). 
Example of myotonic dystrophy type 1 with an autosomal dominant inheritance 
with increasing severity and earlier age of onset from generation to generation due 
to genetic anticipation. 
 
Because of the anticipation event, the most severe phenotype of DM1 
usually appears in new-borns with the congenital form: CDM1 (De 
Temmerman et al., 2004; Rakocevic-Stojanovic et al., 2005; Udd and 
Krahe, 2012). In CDM1, 99% of infants almost always inherit the 
expanded DMPK allele from the mother (Martorell et al., 2007). However, 
paternally inherited anticipation has also been described in the congenital 
form of DM1, but is rare (de Die-Smulders et al., 1997; Zeesman et al., 
2002; Di Costanzo et al., 2009). 
 
Therefore, the size of CTG repeats and the parental sex of the transmitting 
mutation are two main factors that determine the severity of the 
anticipation event (Dean et al., 2006; Pratte et al., 2015). 
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2.3. Molecular pathomechanisms  
The identification of causal mutations in individuals with DM1 has led to 
some hypotheses concerning the molecular pathways underlying this 
disease. Specifically, 3 pathogenic mechanisms have been proposed that 
link the expansions of CTG repeats with clinical manifestations: (i) DMPK 
haploinsufficiency; (ii) an alteration of nearby genes; and (iii) RNA-
induced toxicity (Figure 5).  
 
 
Figure 5. Representation of 3 potential pathogenic mechanisms involved in 
myotonic dystrophy type 1 (DM1). Mutant DMPK allele result in a reduction in 
DMPK protein synthesis (due to haploinsufficiency) as well as a reduction in 
DMWD and/or SIX5 protein expression (due to altered neighbouring genes), 
leading to DM1 phenotypes. The expanded CTG repeats form a stable hairpin 
structure sequestering MBNL proteins and stabilizing CUGBP via 
hyperphosphorylation (due to RNA-induced toxicity) (Modified from Mateos-
Aierdi et al., 2015). 
 
In the haploinsufficiency hypothesis, the reduction in the amount of protein 
synthesized (i.e. DMPK) is attributed to the detrimental effect of having 
only one wild-type copy of the gene in the organism, since the other copy 
contains the CTGexp repeats (Fu et al., 1992). Since DM1 is an autosomal 
dominant disorder, nuclear retention of the mutant RNA could 
theoretically result in a 50% of reduction in DMPK protein. However, 
several studies in mouse model lines indicate that the multisystemic 
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phenotype of DM1 is not caused by haploinsufficiency. Thus, Dmpk 
knockout (KO) mice, in which DMPK protein is fully removed, only 
develop mild myopathy without myotonia and muscle degeneration 
(Reddy et al., 1996; Berul et al., 1999). These data indicate that the loss of 
DMPK function may contribute to the cardiac pathology in DM1, but that 
haploinsufficiency may be not the primary mechanism that explains all the 
DM1 alterations.  
 
The second hypothesis proposes altered expression of genes located nearby 
to the genes responsible for the disease could contribute to the 
pathomechanism of DM1. In accordance, several studies have identified a 
reduced expression of both upstream (DMWD), and downstream (SIX5) 
genes flanking DMPK in DM1 patients (Klesert et al., 1997; Thornton et 
al., 1997). Nonetheless, Six5 KO mice did not recapitulate the multisystem 
phenotype, despite exhibiting a greater susceptibility to develop cataracts 
and cardiac conduction abnormalities (Klesert et al., 2000; Sarkar et al., 
2000; Wakimoto et al., 2002). Therefore, the loss of SIX5 function may 
underlie the development of the cataract phenotype in DM1 but does not 
reproduce major characteristic features of the disease. 
 
During the last decade, RNA-induced toxicity has been proposed as a new 
pathogenic mechanism for diseases caused by expanded repeat sequences, 
such as Huntington disease (La Spada and Taylor, 2010), Fragile X 
syndrome (Swanson and Orr, 2007) and DM1 and DM2 (Mankodi et al., 
2000, Osborne et al., 2009; Gomes-Pereira et al., 2011). 
In DM1, expanded mutations are located within a non-coding region, thus 
the protein sequence of DMPK cannot be altered, but it could have 
detrimental effects at the RNA level. Preclinical studies revealed that the 
expression of ribonuclear foci in muscle fibers was the main factor for the 
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development of muscular features of DM1 in transgenic HSALR mice 
(carrying 250 CTG repeats in the 3’UTR of human skeletal actin (HSA) 
gene), and in transgenic DM300 mice (carrying 300 CTG repeats in the 
3’UTR of DMPK gene) (Mankodi et al., 2000; Seznec et al., 2001). It has 
been described that mutant transcripts form hairpin-shaped secondary 
structures, which interfere with the MBNL family, resulting in their 
sequestration and subsequent loss-of-function (Miller et al., 2000; Tian et 
al., 2000; Mooers et al., 2005). This family of proteins has a key role in the 
regulation of the fetal-adult transition, and its disruption causes splicing 
abnormalities in patients with DM1 (Osborne et al., 2009; Yuan et al., 
2007). The involvement of MBNL proteins in the pathomechanism of 
DM1 was supported by the generation of transgenic mouse lines with 
MBNL deficiencies, including myotonia in Mbnl1 KO mice (Kanadia et 
al., 2003), CNS impairment in Mbnl2 KO mice (Hao et al., 2008; 
Charizanis et al., 2012), and heart and muscle deficits in Mbnl1/Mbnl2 
double KO mice (Lee et al., 2013). Taken together, the toxicity of RNA 
seems to be crucial for promoting the multisystem phenotype seen in 
patients with DM1.  
 
2.4. Ribonuclear foci  
 
A hallmark feature in DM1 is the accumulation of mutated DMPK 
transcripts in ribonuclear inclusions called foci, which are trapped into the 
nucleus of cells disrupting a subset of proteins through MBNL 
sequestration or CELF1 upregulation (Pettersson et al., 2015). Ribonuclear 
foci were first detected in muscle biopsies (Taneja et al., 1995), but have 
also been observed in post-mortem human DM1 brains, mainly in neuronal 
cells of the cerebral cortex, hippocampus, dentate gyrus and thalamus 
(Jiang et al., 2004). These inclusions were also reported in human DM1 
induced pluripotent stem cells (iPS) (Denis et al., 2013). Some evidence 
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suggests that nuclear foci are directly involved in disease pathogenesis 
through a mechanism that involves sequestration of MBNL proteins and 
mis-regulation of alternative splicing (Jiang et al., 2004). In fact, several 
studies reported co-localization of nuclear foci with MBNL proteins 
(Fardaei, 2001; Fardaei et al., 2002; Mankodi et al., 2001), consistent with 
the ability of these proteins to directly interact with expanded CUG repeats 
(Miller et al., 2000; Konieczny et al., 2014). Interestingly, ribonuclear foci 
formation has also been detectd in brains of transgenic DMSXL mice 
carrying more than 1000 CTG repeats (Huguet et al., 2012), and in 
neuronal cells derived from human embryonic stem cells (Marteyn et al., 
2011). Figure 6 shows how toxic RNA foci and CUGexp-associated RBPs 
can deregulate mRNA processing events in DM1 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Cell pathways and signalling cascades deregulated by toxic RNA 
foci in DM1 cells. The expression of toxic RNA foci reduces DMPK protein 
expression, sequesters MBNL proteins and upregulates CELF by PKC activation. 
This results in altered splicing events with fetal isoforms. Finally, increased 
expression of pro-inflammatory cytokines indicates ongoing inflammation in 
DM1 (Modified from Braz et al., 2018). 
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2.5. RNA binding-proteins  
 
RNA-binding proteins play an important role in post-transcriptional events 
promoting splicing, polyadenylation, mRNA stabilization, translation or 
degradation (Peltz et al., 1993; Ruiz-Echevarria and Peltz, 2000; 
Cuchalová et al., 2010). Two main families of RBPs have been recognized 
as key factors in the pathogenesis of DM1 consistent with their ability to 
interact and bind with CUGexp repeats (Paul et al., 2006, 2011): (i) the 
CUG-binding protein (CUG-BP, also known as CELF) and (ii) the MBNL 
family protein. These proteins are antagonistic splicing regulators 
promoting fetal and adult splicing patterns, respectively, that are mis-
regulated in DM1 tissues. However, the individual roles of CELF and/or 
MBNL remaine poorly understood (Figure 7) (Ho et al., 2004; Kuyumcu-
Martinez et al., 2007; Lee and Cooper, 2009; Wang et al., 2015).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. CELF1 gain-of-function and MBNL loss-of-function in DM1 
pathogenesis. Hairpin structure formed by expanded CUG repeats sequesters 
MBNL proteins and upregulates and stabilizes CELF1 protein through 
hyperphosphorilation (Adapted from Lee and Cooper, 2009). 
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2.5.1. CUG-Binding Protein  
 
CUG-BP is a member of the Elav-like family (also known as CELF) 
involved in the regulation of alternative splicing of several pre-mRNAs, 
which has been directly involved in the multisystemic phenotype of 
patients with DM1 (Ladd and Pliam, 2001; Osborne et al., 2009). They are 
proteins present in the nucleus and the cytoplasm with high affinity for 
UG-rich motifs rather than expanded CUG repeats, so they are not 
sequestered in the ribonuclear foci.  
 
In DM1 patients, CELF1 undergo an abnormal activation via protein 
kinase C (PKC) which phosphorylates CELF1, increasing its levels and 
stability mostly in skeletal muscle and heart tissues (Tian et al., 2000; 
Charlet-B et al., 2002; Kuyumcu-Martinez et al., 2007). Moreover, 
increased levels of CELF2 have also been detected in brains of some 
patients with DM1 (Dhaenens et al., 2011). Currently, several lines of 
CELF transgenic mice have been reported (see section 5).  
 
2.5.2. Muscleblind-like protein family  
 
The muscleblind-like (MBNL) protein family is required for muscle 
development, adult photoreceptor differentiation and growth of the 
embryonic peripheral nervous system (Kania et al., 1995; Artero et al., 
1998; Bargiela et al., 2014). In mammals, three genes with different 
expression patterns have been identified: MBNL1, MBNL2 and MBNL3 
(Miller et al., 2000; Fardaei et al., 2002; Kanadia et al., 2003). The 
expression profiles of MBNL proteins are tissue specific. MBNL1 is 
primarily expressed in skeletal muscle and heart, while MBNL2 is 
predominant in the brain. In contrast, MBNL3 expression is mainly found 
in placenta during embryonic development, and in adult skeletal muscle 
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when there is muscle regeneration due to damage (Fardaei et al., 2002; Lee 
et al., 2007; Poulos et al., 2013; Goodwin et al., 2015). This family of 
proteins plays a key role in the regulation of alternative splicing of specific 
pre-mRNAs during developmental transition by promoting adult patterns, 
and their splicing mis-regulation disrupts the conversion of fetal to adult 
protein isoforms (Lin et al., 2006; O’Rourke and Swanson, 2009; Kalsotra 
and Cooper, 2011; Han et al., 2013). Thus, MBNL1 regulates splicing 
patterns during muscle and heart development (Lin et al., 2006; Kalsotra 
et al., 2008), whereas MBNL2 plays a similar role in the CNS (Figure 8) 
(Charizanis et al., 2012; Goodwin et al., 2015). 
 
In DM1 patients, MBNL proteins accumulate in the ribonuclear foci due 
to their high binding affinity to CUGexp repeats, and become sequestered 
(Miller et al., 2000). Because of this, MBNL function is compromised 
resulting in the manifestation of the typical features of DM1. Hence, 
MBNL1 loss-of-function has been related with myotonia, cardiac 
conduction defects and insulin resistance (Ho et al., 2004; Dansithong et 
al., 2005), while MBNL2 loss-of-function has been associated to CNS-
dysfunction, including cognitive decline, hypersomnia, depression and 
anxiety. In fact, studies using relevant Mbnl KO mouse models 
reproducing several phenotypes consistent with DM1 have supported the 
contribution of MBNL loss-of-function to DM1 pathogenesis (see section 
5). 
 
In this thesis, we focused on investigating DM1 neuropathology associated 
with MBNL2 deficiency using a multidisciplinary approach, examinig the 
behavioural, molecular, neurochemical and neurophysiological correlates 
in two transgenic mouse lines lacking the Mbnl2 gene. 
 
INTRODUCTION 
 17 
 
 
Figure 8. Contribution of MBNL1 and MBNL2 to the regulation of 
alternative splicing during fetal-adult transition in the skeletal muscle and 
brain. In a healthy adult, MBNL1 is predominantly expressed in the skeletal 
muscle and MBNL2 in the brain. In a DM1 patient, the RNA foci that sequesters 
MBNL proteins leads to several mis-splicing events with myotonia and muscle 
weakness in the muscle, and brain-specific splicing changes in the brain (taken 
from Kimura et al., 2018).  
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3. Pathophysiological features of DM1  
DM1 is a multi-system condition that impacts nearly every organ of the 
body. The main feature of this disease is myotonia, a delay in relaxation 
after muscle contraction, along with skeletal muscle weakness and atrophy. 
However, patients also develop neuropsychiatric symptoms, resistance to 
insulin, gastrointestinal symptoms and cataracts. This progressive disorder 
imposes a great burden on patients and their families, and the non-muscle 
symptoms increase the negative impact of the disease on their quality of 
life (Laberge et al., 2009; Heatwole et al., 2012). 
 
To date, DM1 is classified into 4 clinical subtypes according to age at the 
onset of symptoms: congenital (CDM1), childhood/juvenile, adult and 
late-onset forms (de Antonio et al., 2016; Ho et al., 2015) (See Table 1 for 
summarize).  
 
CDM1 (>1.000 CTG) mainly consists of severe hypotonia at birth, often 
with a high frequency of respiratory insufficiency, mental retardation and 
progressive muscular dystrophy (Campbell et al., 2013; Echenne et al., 
2013). Affected new-borns have an inverted V-shaped upper lip, also 
named “carp mouth”, a sign of severe facial weakness, which leads to 
difficult breast feeding. All CDM1 patients develop learning disabilities 
and entail special needs. 
 
The childhood- and juvenile-onset forms (50-1.000 CTG) are often 
misdiagnosed in affected adolescents or children due to the absence of 
neurological problems. These forms are less severe than CDM1, but still 
display a variable degree of cognitive and learning impairment, 
particularly with altered psychosocial function, dysarthria (difficulty 
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articulating sounds and words), muscle degeneration and excessive 
sleepiness (Steyaert, 2000; Ho et al., 2019).  
 
The core features of adult-onset DM1 (150-200 CTG) are associated with 
abnormal muscle relaxation related to myotonia, progressive muscle 
weakness and atrophy, accompanied by extra-muscular symptoms like 
cardiac arrhythmias, cataracts, CNS impairment, excessive daytime 
sleepiness, gastrointestinal problems and insulin resistance (Thornton, 
2014; Mejersjö and Kiliaridis, 2017; Gourdon and Meola, 2017). The late-
onset form (50-100 CTG) is characterized by a milder phenotype with less 
muscle contribution including mild myotonia and early cataracts 
(Arsenault et al., 2006). Moreover, an age-related cognitive involvement 
can be present (Modoni et al., 2004). 
 
Table 1. Summary of myotonic dystrophy type 1 phenotypes, clinical findings 
and CTG repeat length. 
 
Subytpe 
 
Age of 
onset 
 
Clinical findings  
 
CTG 
length 
 
Congenital (CDM1) 
 
At birth 
Hypotonia                                                                          
Respiratory failure                                                                   
Intellectual disability 
 
>1.000 
 
Childhood/Juvenile 
onset 
 
1-20 
Facial weakness and 
myotonia                                                                                
Cardiac conduction 
abnormalities                            
Low IQ 
 
100-
1.000 
 
 
Adult-onset 
 
 
20-30 
Weakness and myotonia                                                                    
Cardiac conduction 
defects                  
Insulin resistance                       
Cataracts                               
Cognitive impairment 
 
50-
1.000 
 
 
Late-onset 
 
 
>40 
Mild weakness and 
myotonia                                                                     
Cataracts                                                                       
Aging-related cognitive 
decline 
 
50-100 
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3.1. Peripheral Phenotype  
The cardinal symptoms in adult-onset DM1 are skeletal muscle weakness, 
atrophy and myotonia with a distal pattern, leading to difficulties in 
performing tasks requiring fine manual dexterity.  
Myotonia is defined as a delay muscle relaxation after a voluntary muscle 
contraction caused by muscle hyperexcitability. However, handgrip 
myotonia and strength may improve with repeated contractions called the 
“warm-up” phenomenon (Logigian et al., 2005). From a molecular point 
of view, it has been indicated that myotonia is caused by an incorrect 
splicing of the chloride channel 1 due to mis-regulated MBNL1 and 
CUGBP1 (Meola et al., 2013). 
 
Muscle wasting and weakness is the second most prominent clinical 
feature in DM1, affecting social activities, employment, and many aspects 
of their patients’ daily life. Muscle wasting also affects eye movement, 
speech, swallowing and breathing. Moreover, DM1 patients exhibit a 
typical facial appearance known as “hatchet face” or “myopathic face”, 
mainly caused by weakness and atrophy of the facial muscles and palpebra 
elevators. The molecular mechanisms of muscle wasting have not yet been 
identified. Other peripheral features present in DM1 include ocular 
manifestations with an early onset of cataracts, cardiovascular involvement 
characterized by arrhythmias and cardiac conduction defects (Groh et al., 
2012) and endocrine and gastrointestinal dysfunction (Ørngreen et al., 
2012; Rönnblom et al., 1996). 
 
There are not many studies focusing on gender differences among patients 
with DM1, but recently it has been reported that women lose less grip 
strength and have greater dexterity than men in upper limb performance 
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(Raymond et al., 2017), and that men have higher morbidity and mortality 
than women with DM1 (Dogan et al., 2016). 
DM1 is a chronic disease due to progressive muscle wasting and weakness, 
dysphagia, respiratory failure, or fatal arrhythmias. Although currently 
there is no cure for DM1, care therapy is focused on treatments designed 
to provide symptomatic relief and support. To date, only mexiline, a 
sodium channel blocker, can be considered relevant to treat myotonia. 
However, this drug has a potential pro-arrhythmic effect, and thus, its use 
is contraindicated in DM1 patients with a high risk of cardiac pathology 
(Logigian et al., 2010).   
 
3.2. Central Nervous System Alterations 
While most research has focused on the neuromuscular features of DM1, 
patients and families report that CNS-related sympthomatology is usually 
the most challenging and difficult to deal with (Antonini et al., 2006; 
Bugiardini et al., 2013; Dogan et al., 2016). Although CNS alterations in 
DM1 are well stablished, they are not well characterized. The major and 
most frequent symptoms include cognitive deficits, depression (Winblad 
et al., 2010), anxiety-linked behaviours (Meola et al., 2003; Van der 
Velden et al., 2019), emotional deficits (Bungener et al., 1998), excessive 
daytime sleepiness (Gallais et al., 2014), and fatigue (Winblad and 
Lindberg, 2019). 
 
3.2.1. Cognitive function  
Cognition is defined as the mental process of acquiring knowledge and 
understanding throught experience, thought and senses. It comprises a 
broad range of intellectual functions such as attention capacity, stimulus 
perception, memory and executive functions, all needed in everyday 
scenarios.  
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In the adult-onset form of DM1, global cognitive function is usually 
impaired. These cognitive alterations include deficits in executive 
functions, attention and visuo-spatial abilities, suggesting a frontal 
dysexecutive syndrome (Rubinsztein et al., 1998; Meola and Sansone, 
2007; Romeo et al., 2010; Okkersen et al., 2017), and some studies have 
reported the progressive nature of these impairments (Gallais et al., 2017; 
Sansone et al., 2007; Winblad et al., 2016). Factors such as age-related 
decline or motor problems could affect cognitive performance in these 
patients and should be ruled out in clinical studies as possible confounding 
issues (Modoni et al., 2004; Gaul et al., 2006). Moreover, patients with 
DM1 also exhibit social cognition deficits. They often show reduced ability 
to recognize facial expressions or infer mental states from other people 
(Kobayakawa et al., 2010, 2012; Serra et al., 2016a; Winblad et al., 2016).  
 
3.2.2. Affective alterations 
Affective alterations are common neuropsychiatric features in DM1. 
Depression is one of the main health problems in DM1 due to its high 
prevalence and incapacitating effects (Antonini et al., 2006; Minier et al., 
2018; Van der Velden et al., 2019). Winblad et al. (2010) identified clinical 
depression in 32% of DM1 patients. This depressive condition ranged from 
mild to moderate and was mainly associated with early stages of the 
disease, and a higher educational level (Koenigs et al., 2008; Winblad et 
al., 2010). Morever, higher levels of anxiety, apathy, reduced initiative and 
fatigue are also present in DM1 patients, and may be linked to depression 
(Antonini et al., 2006; Van der Velden et al., 2019).  
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3.2.3. Excessive daytime sleepiness and fatigue 
Excessive daytime sleepiness (EDS) and fatigue are prominent complaints 
among DM1 patients with a significant impact on the patient’s quality of 
life (Heatwole et al., 2012). EDS is a common and incapacitating feature 
of DM1 with a prevalence in some populations that reaches 88% (Ciafaloni 
et al., 2008; Heatwole et al., 2012). EDS is characterized by 
hypersomnolence and usually occurs in situations of monotony or when no 
attention is being paid, not during activity (Laberge et al., 2013). 
Furthermore, rapid eye movement (REM) sleep deregulation and increased 
nighttime sleep propensity has been described (Laberge et al., 2009; 
Heatwole et al., 2012). Fatigue is a major complaint reported by DM1 
patients and may be unrelated to sleep quality (Angelini and Tasca, 2012; 
Heatwole et al., 2012). It involves central and peripheral components and 
may be due to CNS dysfunction, muscle weakness, depression or thyroid 
dysfunction (Baldanzi et al., 2017).  
 
There are very few studies investigating potential therapeutic interventions 
for CNS-related disturbances in DM1. Up to now, only modafinil, a 
compound normally used for excessive somnolence, has shown some 
efficacy for treating EDS and fatigue (MacDonald et al., 2002). As 
cognitive impairment and depression have been associtated with worse 
quality of life in DM1 patients, there is an impending need to improve these 
problems (Antonini et al., 2006; Laberge et al., 2013; Rakocevic-
Stojanovic et al., 2014). Some non-pharmacological interventions have 
been effective for improving cognitive functions in DM1 patients, such as 
cognitive behavioural therapy (Okkersen et al., 2018; Winblad and 
Lindberg, 2019). However, there are currently no medications available to 
treat both the cognitive alterations and depressive state associated with 
DM1.  
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4. Neuropathological correlates of DM1
4.1. Histopathological evidence 
A variety of histopathological features have been observed in post-mortem 
brain samples of DM1 patients. These neuropathological studies 
documented neuronal loss, neurofibrillary degeneration and abnormal 
TAU protein expression in brain tissues. 
4.1.1. Neuronal loss 
Reduced neuronal densities have been reported in specific areas of the 
brainstem in DM1 patients. In particular, primary degeneration of 
cathecolaminergic and serotonin neurons in medullary and rahpe nuclei, 
repectively, has been considered as a possible neuropathological correlate 
of hypersomnolence and hypoventilation (Ono et al., 1998a, 1998b). 
Moreover, neuronal loss in the superficial layer of the frontal and parietal 
cortices and in deep layers of the occipital cortex has also been reported 
(Mizukami et al., 1999), which may contribute to several behavioral and 
cognitive problems observed in patients with DM1.  
4.1.2. Neurofibrillary degeneration 
Neurofibrillary degeneration is an age-related process that occurs during 
normal aging and is abnormally increased in neurodegenerative diseases. 
It consists of intracellular aggregates of insoluble fibers and 
hyperphosphorylated microtubule-associated tau proteins, which form 
neurofibrillary tangles (NFTs) (Sergeant et al., 2001; Buée et al., 2010). 
Some studies indicate that the accumulation of NFTs may be key for the 
development and progression of brain dysfunction (Maurage et al., 2005; 
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Winblad et al., 2008). Post-mortem studies have described significant 
changes in specific tau isoforms in the hippocampus, entorhinal and 
temporal areas of DM1 brain tissue (Vermersch et al., 1996; Sergeant et 
al., 2001; Maurage et al., 2005). Moreover, tauopathy in DM1 brain tissue 
was associated with larger CTGexp repeats (Sergeant et al., 2001). 
4.2. Structural and functional alterations in DM1 
brains 
In the last decade, a significant number of imaging studies have confirmed 
DM1 as a brain disease. Magnetic resonance imaging (MRI) studies in 
DM1 patients showed white matter hyperintense lesions mainly located in 
frontal and temporal lobes (Di Costanzo et al., 2001; Romeo et al., 2010; 
Minnerop et al., 2011, 2018; Wozniak et al., 2014). In addition, callosal 
body atrophy has been described in adult-onset form of DM1 along with 
degradation of major pathways in the limbic system (Minnerop et al., 
2011). Paradoxically, significant positive correlations have been found 
between white matter integrity and motor function, depression and 
hypersomnia/fatigue (Minnerop et al., 2011). In accordance, DM1 patients 
with longer disease duration, and presence of white matter lesions, 
exhibited fewer depressive symptoms (Winblad et al., 2010).  
Gray matter alterations in DM1 have been observed in the cortex and in 
subcortical structures, such as the thalamus and the basal ganglia (Antonini 
et al., 2004; Weber et al., 2010; Minnerop et al., 2011; Baldanzi et al., 
2016). Other abnormalities like dilated ventricles, could also be attributed 
to reduced grey matter (Schenider-Gold et al., 2015; Zanigni et al., 2016). 
On a structural level, global brain atrophy is linked with impaired motor 
functions such as planning and execution actions (Mitsuoka et al., 2003), 
INTRODUCTION 
 27 
whereas white matter disruption has been associated with cognitive deficits 
including working memory, executive function, visuo-spatial impairment 
and attention deficits (Weber et al., 2010; Wozniak et al., 2013, 2014; Caso 
et al., 2014; Baldanzi et al., 2016).  
 
Functional MRI (fMRI) studies have revealed changes in resting state 
connectivity in DM1 (Serra et al., 2014, 2016) with altered cerebral cortical 
circuits, mainly in white matter regions (Minnerop et al., 2011). Increased 
activity is found in motor regions during the performance of a motor task, 
while in DM1 patients with myotonia, there was no activation of these 
motor areas, indicating that there is no involvement of brain function in the 
development of myotonia (Caramia et al., 2010; Toth et al., 2015). In 
resting-state MRI studies, abnormal connectivity networks were described 
in regions related to personality profiles and social cognition (Serra et al., 
2016a, b).  
 
Altogether, correlation analysis between brain pathological changes and 
cognitive function indicate that complex neural networks, involving 
numerous CNS structures and mechanisms related to plasticity, 
neurodevelopment and neurodegeneration are involved in DM1. 
Therefore, it is important to carry out long-term studies to determine if the 
symptoms vary (neurodegeneration) or remain stable 
(neurodevelopmental) over time. In this sense, Winblad et al. (2016) 
reported that cognitive decline in adult-onset DM1 correlated with earlier 
onset and longer disease duration, indicating a neurodegenerative process.  
 
Complementing MRI studies, in vivo proton magnetic resonance 
spectroscopy (1H-MRS) allows analysing alterations in metabolite 
concentrations in different brain regions. The most commonly measured 
metabolites are N-acetylaspartate (NAA), choline (Cho), and creatine (Cr). 
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NAA is a marker of neuronal function since it is expressed in the cytosol, 
axons and synaptosomes of neurons, and a decrease in this metabolite 
correlates with a neuronal dysfunction or neuronal loss. Cho is often used 
as a glial marker, which predicts a cell proliferation or gliosis process, and 
Cr is the compound peak used as control housekeeping expressed 
everywhere in the brain. Since estimating absolute levels of metabolites in 
vivo is difficult, the content is measured in relation to other molecules. 
 
Previous studies reported altered NAA/Cho and NAA/Cr ratios in adult-
onset DM1 patients, showing a decrease in NAA production in 
temporoparietal grey matter, and a more pronounced attenuation in frontal 
white matter (Hashimoto et al., 1995; Akiguchi et al., 1999; Vielhaber et 
al., 2006; Takado et al., 2015). Accordingly, post-mortem DM1 brains 
exhibited cerebral neuronal loss along with myelin abnormalities (Ogata et 
al., 1998; Mizukami et al., 1999). Moreover, a significant increase in 
glutamine, and reduced glutamate in the frontal cortex has been also 
observed (Takado et al., 2015) These abnormalities in the glutamatergic 
system of DM1 patients, could be related to a synaptic dysfunction, as 
previously demonstrated in post-mortem brains (Charizanis et al., 2012; 
Hernandez-Hernandez et al., 2013). 
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5. Preclinical models of DM1  
The generation of animal models that faithfully reproduce a particular 
disease presents a unique opportunity not only to understand the 
mechanisms involved, but also to screen, identify and evaluate new 
pharmacological therapies. Several animal models of DM1 have been 
developed and have provided information to associate disease mutations 
with the resulting phenotypes.  
 
To model the disease, invertebrate and vertebrate animals have been used. 
The fruit fly Drosophila melanogaster and the zebrafish model Danio rerio 
have been widely utilized as model organisms to study RNA toxicity of 
expanded CUG repeats (de Haro et al., 2006; Garcia-Lopez et al., 2008; 
Plantié et al., 2015). However, the mouse has proven to be more useful for 
gaining deep insight into DM1 pathomechanism (Mankodi et al. 2000, 
Seznec et al., 2000, Gomes-Pereira et al., 2007; Timchenko et al., 2004; 
Ward et al., 2010). Here, we will summarize the data regarding two 
different categories: (i) models of toxic RNA expression and (ii) models of 
altered RBPs such as MBNL sequestration or CELF1 overexpression (see 
Table 2 for summary). 
 
To assess the contribution and toxicity of foci formation to the multisystem 
pathology observed in patients with DM1, several animal models have 
been generated. Drosophila models have managed to reproduce genetic, 
molecular and histological aspects of the disease and have been used as a 
tool to discover new components in the pathogenesis pathway of the 
disease, as well as potential drugs for the treatment of the disease (Garcia-
Lopez et al., 2008; Garcia-Lopez et al., 2011; Fernandez-Costa et al., 2013; 
Garcia-Alcover et al., 2014). 
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Many mouse models have been developed to investigate the underlying 
mechanisms of DM1, but only a few transgenic lines showed CNS-related 
phenotypes. These include DM300 and DMSXL mice, and the inducible 
mouse model EpA960. These CTG-expressing lines in the CNS 
recapitulated molecular, behavioral and neurochemical characteristics, 
thus becoming robust models of the pathology of the CNS of DM1. 
 
On the other hand, the use of the HSALR mouse is restricted for the 
investigation of skeletal muscle pathology in adults, despite not 
recapitulating muscle wasting and weakness (Mankodi et al., 2000). 
However, this mouse model corroborates that promoting a specific muscle 
expression of CUGexp repetitions is enough to trigger a DM1-like muscle 
degeneration phenotype and provides crucial evidence of the toxicity of 
RNA protein aggregates in DM1 disorder.Moreover, the characterization 
of molecular and physiological phenotypes resulting from CELF1 
upregulation and MBNL sequestration in mice, regardless of expanded 
CTG repeats, has illustrated the central role of these two protein families 
of splicing regulators in the pathogenesis of DM1. These mouse lines 
recapitulated most of the phenotypic features of DM1, indicating that foci 
itself are not required for DM1 pathogenesis. 
 
Mouse models of CELF1 upregulation have shown that the toxicity of 
CELF1 is sufficient to reproduce phenotypes such as those observed in 
congenital DM1, but due to their limitations of high mortality and difficult 
reproduction, inducible lines of CELF1 overexpression in skeletal muscle 
were developed (Ward et al., 2010) and the heart (Koshelev et al., 2010) 
reproducing functional and molecular abnormalities observed in patients 
with DM1. Therefore, CELF proteins can also regulate the alternative 
splicing of transcripts involved in neuronal function and may contribute to 
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the etiology of neurological disorders already described in patients with 
DM1 (Ladd, 2013). 
 
On the other hand, the expression of increased CTGexp repeats also induces 
the sequestration of the three MBNL proteins in the RNA foci (Miller et 
al., 2000; Mankodi et al., 2001; Fardaei et al., 2002). The involvement of 
these proteins in DM1 pathology was confirmed by the generation of KO 
mouse lines through the depletion of Mbnl genes alone, or by inactivating 
multiple Mbnl genes at once. These mouse models allowed to establish the 
functional role of the MBNL family and its contribution to DM1 molecular 
pathogenesis.  
 
Regarding MBNL1, the generation of the constitutive Mbnl1 KO mice 
revealed a crucial role of MBNL1 in the specific control of the fetal-adult 
transition in the muscle (Suenaga et al., 2012). However, did not develop 
muscle weakness. Therefore, the recruitment of other MBNL proteins may 
be necessary to fully replicate the multisystemic DM1 phenotype. In line 
with the hypothesis that MBNL1 downregulation causes the major 
muscular-phentoypes of DM1 and aberrant splicing events, Kanadia et al. 
(2006) used adeno-associated virus (AAV) to overexpress MBNL1 in 
transgenic HSALR mice, and rescued myotonia and adult splicing events 
(Kanadia et al., 2006). MBNL2 contribution was also tested in the Mbnl2 
KO mouse model which showed marked CNS phenotypes, along with 
brain-specific splicing changes (Charizanis et al., 2012). These results 
suggest that the main pathological changes in DM1 brains are attributable 
to the expression of toxic RNA, with the subsequent MBNL2 
sequestration, and deregulation of specific alternative splicing events 
essential for normal CNS function in adults. 
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Moreover, MBNL3 loss of function was also examined using the Mbnl3 
KO mice which showed pathologies associated with age, such as insulin 
resistance, heart defects and cataracts, suggesting that loss of MBNL3 
function may contribute to premature aging (Choi et al., 2016). Despite 
finding significant phenotypes in the depletion lines of a single Mbnl gene, 
they do not faithfully recapitulate all the features of DM1. It could be 
probably due to the compensatory mechanisms of the other Mbnl isoforms 
(Lee et al., 2013). For example, in Mbnl1 KO mouse, the expression of 
Mbnl2 is upregulated and MBNL2 protein binds to target transcripts that 
are normally regulated by MBNL1 (Lee et al., 2013). Therefore, MBNL-
like compound KO mice have been generated to recreate a most human-
like DM1. The double KO of Mbnl1 and Mbnl2 mouse was lethal in 
embryonic stages, suggesting a crucial role of these proteins during 
development (Lee et al., 2013). These findings revealed that the 
simultaneous deletion of various MBNL proteins is a critical event in the 
pathogenesis of DM1. 
 
Altogether, by generating and characterizing individual and compound 
Mbnl KO mouse models, it has been shown that simultaneous sequestration 
of MBNL proteins are crucial for the development of clinical features of 
DM1. Due to limited availability and technical difficulties of working with 
human DM1 tissue, constitutive and conditional Mbnl KO mouse models 
allow for the investigation of altered RNA processing in multiple tissues, 
cell types and developmental phases. 
 
In this thesis, we used Mbnl2 KO mice to examine more in depth the 
behavioural, neurochemical and neurophysiological correlates of a 
constitutive loss of MBNL2 in the brain. In addition, we investigated the 
progression of these alterations, and studied whether gender differences 
existed. 
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Table 2. Summary of the most relevant transgenic animal models of myotonic 
dystrophy type 1.  
MODELS OF RNA TOXICITY 
Drosophila480 
Expressing 480 CTG repeats in mushroom bodies leading to muscle 
wasting and degeneration (de Haro et al., 2006; García-López et al., 2008) 
Drosophila960 
Expressing 960 CTG repeats in the larval muscles leading to myoblast 
fusion defects, muscle hypercontraction and reduced fiber size (Picchio et 
al., 2013)  
HSALR 
Expressing 250 CTG repeats in the Human Skeletal Actin gene 
promoter.                                                                                               
Skeletal muscle: Myotonia and muscle degeneration (Mankodi et al., 2000) 
DM300 
Expressing 300 CTG repeats with a high frequency of intergenerational 
instability.  
Skeletal muscle and CNS: Myotonia and altered tau protein isoforms in 
brain (Seznec et al., 2001; Guiraud-Dogan et al., 2007). 
DMSXL 
Expressing >1.000 CTG repeats in the DMPK locus. 
Muscle: Muscle deficits with disrupted motor performance (Gomes-Pereira et 
al., 2007; Huguet et al., 2012) 
Brain: Anxiety, spatial and working memory impairment, anhedonia and 
deficits in short-term plasticity (Hernández-Hernández et al., 2013) 
EpA960 
Inducible and tissue-specific mouse line expressing 960 CTG repeats in 
human DMPK gene. 
Heart: Cardiac pathology with arrhythmias (Wang et al., 2007) 
Skeletal muscle: Progressive muscle impairment (Orengo et al., 2008) 
Brain: Learning deficits, impaired hippocampal LTP and reduced 
synaptic transmission (Wang et al., 2017) 
MODELS OF ALTERED RNA-BINDING PROTEINS 
CELF1 O.E 
CELF1 overexpression in heart tissue and skeletal muscle. 
Severe growth retardation, delayed myogenesis and elevated neonatal 
mortality similar to congenital DM1 phenotype (Timchenko et al., 2004; Ho et al., 
2005) 
MBNL1 O.E 
MBNL1 overexpression in skeletal muscle. 
Phenotype: Improved skeletal muscle (Chamberlain and Ranum, 2012) 
Mbnl1 KO  
Inactivation of MBNL1 impacted mainly in skeletal muscle and eye.  
Phenotype: Myotonia, cataracts and cardiac defects (Kanadia et al., 2003) 
Mbnl2 KO  
Inactivation of MBNL2 impacted mainly in CNS, with no muscle 
affection. 
Phenotype: hypersomnia, learning and spatial memory impairment, 
decreased synaptic plasticity (Charizanis et al., 2012) 
Mbnl3 KO  
Inactivation of MBNL3 impacted mainly in skeletal muscle. 
Phenotype: impaired muscle regeneration and progressive wasting and 
weakness (Polulos et al., 2013) 
O.E: overexpression 
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6. Therapeutic strategies in animal models of DM1 
The investigations in animal models have improved our understanding of 
the molecular pathogenesis of DM1 and have opened new avenues in the 
search for therapeutic targets. Based on the accumulated evidence, two 
major therapeutic approaches, mostly for mytonia, have been conducted in 
animal models: (i) silencing strategies to reduce RNA toxicity, and (ii) 
inhibiting interactions between MBNL and toxic RNA. These strategies 
include the use of antisense oligonucleotides (ASOs), small interfering 
RNAs (siRNAs), microRNAs (miRNAs) and pharmacological approaches 
with small molecules (see Figure 9).  
 
6.1. Degradation of toxic RNA 
 
In recent years, numerous works have focused their efforts on reducing the 
expression of mutant transcripts through their degradation (Francois et al., 
2011; Gonzalez-Barriga et al., 2013). ASOs are of interest for their 
capacity to discriminate between mutant and normal transcripts and they 
are designed to disperse intranuclear foci. Preclinical studies showed that 
intramuscular injections of ASOs reduced foci number, and improved 
myotonia in HSALR (Wheeler et al., 2009) and in DMSXL mice (Mulders 
et al., 2009). Given that DM1 is a multisystemic disorder that affects 
multiple tissues and organs, many studies have been conducted to 
investigate the systemic effects of a new type of ASOs called “gapmer”, 
with a that degrades mRNA (Chan et al., 2006). These gapmer-ASOs have 
reached the clinical stage after showing high efficacy in HSALR (Wheeler 
et al., 2012), and DMSXL mice (Jauvin et al., 2017), and in monkeys 
(Pandey et al., 2015). Taken together, antisense technology has significant 
potential to target specific genes in diseases that involve increased protein 
or RNA function (Bennett and Swayze, 2010). 
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On the other hand, siRNAs exert their gene-silencing effect within the 
RNA interference (iRNA) pathway. Once inside a cell, siRNAs are 
recognized by proteins in the RNA-induced silencing complex (RISC), 
activating and cleaving the mRNA (Garber, 2017). Both intramuscular and 
systemic delivery of siRNA molecules, reduced toxic transcripts and 
improved muscular phenotypes in HSALR mice (Sobczak et al., 2013; 
Bisset et al., 2015). More recently, in vivo administration of miRNAs has 
demonstrated beneficial effects in Drosophila DM1 model (Cerro-
Herreros et al., 2016) and its administration in quadriceps muscles 
in HSALR mice, upregulated MBNL protein, and rescued the 
molecular, cellular and functional defects of DM1-muscle pathology 
(Cerro-Herreros et al., 2018). 
 
6.2. Inhibition of CUGexp-MBNL interaction 
 
Several research groups have developed therapeutic approaches based on 
small molecules to treat disease-related phenotypes by the inhibition of 
CUGexp-MBNL interaction or by the upregulation of MBNL1 (Kumar, 
2012; Parkesh et al., 2012; Chen et al., 2012; Ketley et al., 2014). Thus, 
hundred of molecules have emerged in screening assays with cell and fly 
DM1 models (Garcia-Alcover et al., 2014; Yildirim et al., 2015; Luu et al., 
2016; Konieczny et al., 2017). Recently, the peptide ABP1 was discovered 
using the Drosophila model. This peptide suppressed the RNA toxicity by 
preventing hairpin formation, and reduced muscle histopathology in 
HSALR mice (Garcia-Lopez et al., 2011). 
 
However, among the drugs that are already approved by the FDA (also 
known as drug repositioning), the most relevant are: pentamidine, 
actinomycin D, erythromycin and phenylbutazone. Pentamidine, was the 
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first small molecule identified that disrupted toxic RNA foci, released 
MBNL1 protein and reversed splicing defects. The beneficial effects of this 
antibiotic drug have been reported in HSALR mice (Warf et al., 2009) and 
Drosophila DM1 model (Chakraborty et al., 2015). Actinomycin D and 
erythromycin demonstrated an improvement of myotonia and splicing 
defects in HSALR mice (Siboni et al., 2015; Nakamori et al., 2016). 
Phenylbutazone, a non-steroidal anti-inflammatory drug (NSAIDs), 
upregulated the expression of MBNL1 protein and ameliorated splicing 
defects improving wheel-running activity in HSALR mice (Chen et al., 
2016).  
 
In addition, CELF proteins are also targets to consider. CELF activity is 
controlled by PKC and glycogen synthase kinase-3 beta (GSK3β), which 
are increased in skeletal muscle of DM1 patients. Thus, inhibitors of those 
proteins have been shown to reverse muscle and cardiac phenotypes in DM 
mouse models (Wang et al., 2009; Jones et al., 2012). Tideglusib, a GSK3β 
inhibitor, reduced CUGexp levels and enhanced muscle pathology in HSALR 
mice and increased postnatal survival, and improved growth and 
neuromotor activity in DMSXL mice (Wang et al., 2016). These findings 
indicate that GSK3β inhibitors can correct the pathology of DM1 through 
several pathways.  
 
Although all these studies provide promising results regarding potential 
treatment options for the muscular deficits observed in DM1, there is a lack 
of research focusing on possible therapeutic alternatives for the CNS 
deficits associated to this pathology. In this sense, the Drosophila fly 
model of DM1 expressing 480 CTG repeats in mushroom bodies, which 
are brain centres for associative learning, and affects only females has 
provided a relevant tool to screen chemical suppressors of neuronal 
toxicity related to CUGexp RNA (Garcia-Lopez et al., 2008). This fly model 
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triggers a semi lethal phenotype in pupal female flies. Therefore, 
compounds that increase the viability of female flies, would be compounds 
with anti-DM1 properties. After testing 400 candidate drugs from the 
Prestwick Chemical Library, 10 chemical compounds with diverse 
mechanisms of action were shown to significantly improve the viability of 
female flies (Garcia-Lopez et al., 2008). These included non-steroidal anti-
inflammatory agents, muscarinic, cholinergic, histamine receptor 
inhibitors, and monoamine uptake inhibitors.  
 
Taking advantage of these data, in this thesis we selected the 
psychostimulant methylphenidate, which increases dopamine by blocking 
dopamine transporters (Garcia-Lopez et al., 2008), as a potential 
therapeutic strategy for CNS alterations in DM1 using constitutive Mbnl2 
KO mice (Article 1).  
Figure 9. Therapeutic strategies for DM1. Antisense oligonucleotides and 
siRNAs restore MBNL function by degrading the toxic RNA of hairpin structures. 
Small molecules such as pentamidine and phenylbutazone increase the expression 
of MBNL1 by inhibiting the CUGexp-MBNL interaction.  
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General objective 
 
Although extensive data support the involvement of the Mbnl2 gene in CNS 
pathology in DM1, there is a lack of studies investigating the 
neurobiological correlates of CNS alterations related to MBNL2 
deficiency. Thus, the main goal of this thesis was to investigate novel 
mechanisms relevant to DM1 using (i) constitutive Mbnl2 KO mice and (ii) 
tissue-specific KO mice, where Mbnl2 expression is selectively deleted in 
the glutamatergic neurons of the forebrain (Mbnl2NEX-Cre).  The second aim 
of this thesis was to find novel therapeutic avenues to alleviate the 
neuropsychological disturbances associated to loss of MBNL2 function.   
 
Specific objectives 
 
1) To study the progression of behavioural alterations in male and female 
mice associated to a constitutive loss of MBNL2 protein, and to 
determine the cellular, neurobiochemical, molecular and 
eletrophysiological correlates of these deficits (Article 1). 
 
2) To evaluate the potential therapeutic use of the psychostimulant 
methylphenidate and elucidate its mechanisms of action in constitutive 
Mbnl2 KO mice (Article 1). 
 
3) To assess the role of the Mbnl2 gene in forebrain glutamatergic neurons 
in the behavioural and brain disturbances related to DM1 and 
investigate the associated neurobiological correlates (Article 2). 
 
4) To examine the potential therapeutic use of the atypical antidepressant 
mirtazapine and explore its mechanisms of action in tissue-specific 
Mbnl2NEX-Cre mice (Article 2).  
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ARTICLE 1 
Methylphenidate Attenuates the Cognitive and Mood Alterations 
Observed in Mbnl2 Knockout Mice and Reduces Microglia 
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Abstract 
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder 
characterized by muscle weakness and wasting and also by important 
central nervous system-related symptoms including impairments in 
executive functions, spatial abilities and increased anxiety and depression. 
The Mbnl2 gene has been implicated in several phenotypes consistent with 
DM1 neuropathology. In this study, we developed a tissue-specific 
knockout mouse model lacking the Mbnl2 gene in forebrain glutamatergic 
neurons to examine its specific contribution to the neurobiological 
perturbations related to DM1. We found that these mice exhibit long-term 
cognitive deficits and a depressive-like state associated with neuronal loss, 
increased microglia and decreased neurogenesis, specifically in the dentate 
gyrus (DG). Chronic treatment with the atypical antidepressant mirtazapine 
(3 and 10 mg/kg) for 21 days rescued these behavioral alterations, reduced 
inflammatory microglial overexpression, and reversed neuronal loss in this 
brain structure. We also show that mirtazapine re-established 5-HT1A and 
histaminergic H1 receptor gene expression in the hippocampus. Finally, 
metabolomics studies indicated that mirtazapine increased serotonin (5-
HT), noradrenaline (NA), gamma-aminobutyric acid (GABA) and 
adenosine. These data suggest that loss of Mbnl2 gene in the glutamatergic 
neurons of the DG may underlie the most relevant DM1 neurobiological 
and behavioral features and provide evidence that mirtazapine could be a 
novel potential candidate to alleviate these debilitating symptoms in DM1 
patients. 
 
Key-words: DM1; tissue-specific Mbnl2 knockout mice; glutamate; 
depression; cognitive deficits; neuronal loss; inflammation; dentate gyrus; 
adenosine; GABA; mirtazapine.  
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1. INTRODUCTION 
 
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder caused by an 
RNA gain-of-function in which pathological CTG repeats generate toxic 
RNAs that sequester, most prominently, the muscleblind-like (MBNL) 
proteins (Fardaei et al., 2002). While MBNL1 is required for skeletal and 
cardiac muscle development, MBNL2 is highly expressed in the central 
nervous system (CNS) and MBNL3 is more related to placenta and fetal 
stage (Miller et al., 2000; Goodwin et al., 2015). Some of the features in 
adult-onset DM1 include muscular symptoms, cardiac arrhythmias, insulin 
resistance and cerebral atrophy (Gourdon and Meola, 2017). Also, 
cognitive impairments, increased anxiety and depression have been 
reported, indicating a dysfunction of the frontal and temporo-parietal 
regions (Sansone et al., 2007; Modoni et al., 2008; Winblad et al., 2016; 
Gallais et al., 2017). Accordingly, imaging studies have confirmed the 
widespread alteration of cortical and subcortical regions among patients 
with DM1 (Cabada et al., 2017; Minnerop et al., 2018). Moreover, loss of 
dopamine (DA) and serotonin (5-HT) neurons, reduced N-acetylaspartate 
and reduced glutamate (Glu) were found in brains of DM1 patients (Ono et 
al., 1998a, 1998b; Vielhaber et al., 2006; Takado et al., 2015). Although 
these data point to deregulation of some neurotransmitter systems in the 
brains of DM1 patients, there is lack of evidence regarding the 
neurobiological mechanisms involved, and no specific treatments exist for 
the neuropathology associated with this disabling disease (Heatwole et al., 
2012). 
 
Only a few animal models of brain-related alterations in DM1 have been 
developed to investigate the neurobiological substrates of this disease 
(Hernández-Hernández et al., 2013; Wang et al., 2017; Charizanis et al., 
2012). Moreover, studies in Drosophila flies expressing CUG repeats that 
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reproduce key features of DM1 disease, such as mis-regulated alternative 
splicing of muscle genes, Mbnl sequestration in the CNS, and CUG-
dependent CNS alterations (de Haro et al., 2006), have been useful for 
screening new treatment strategies. In this sense, suppression of brain 
DM1-like phenotypes in this fly model has been reported using several 
compounds with diverse pharmacological activity (García-Lopez et al., 
2008). One class of compounds that suppressed the DM1-related 
neurotoxicity in this fly model specifically acted on dopaminergic neurons. 
In accordance, we have previously reported that constitutive Mbnl2 KO 
mice exhibiting cognitive impairment and affective deficits associated to 
DM1 neuropathology were reversed by chronic treatment with the 
psychostimulant methylphenidate (Ramon-Duaso et al., 2019).  
In searching to identify novel candidates with therapeutic potential for DM1 
brain phenotypes, in this study we employed the same model already used 
for previous drug screening; the transgenic Drosophila model to assess up 
to 1200 candidate drugs in functional studies. Among the chemical 
suppressors of DM1 toxicity found, the atypical antidepressant mirtazapine 
(MRZ) was selected because of its promising pharmacological profile to 
further investigate its potential beneficial effects in a mouse model of DM1 
Since our previous data showed that constitutive Mbnl2 KO display 
behavioral alterations associated with major neurobiological changes in the 
mPFC and HPC (Ramon-Duaso et al., 2019), here we developed a tissue-
specific mouse model lacking the Mbnl2 gene in glutamatergic neurons of 
the neocortex and HPC using the Cre-Lox system, and assessed the effects 
of MRZ on brain and behavioral alterations. MRZ is a noradrenergic and 
specific serotonergic antidepressant (Berton and Nestler, 2006), 
characterized by antagonistic activities at presynaptic α2-adrenergic, 5-HT2 
and 5-HT3 receptors and by a 5-HT1A agonistic activity (De Boer, 1996). 
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Interestingly, MRZ can enhance cognitive performance in depressed and 
schizophrenic patients (Borkowska et al., 2007; Stenberg et al., 2011). 
 
Hence, in this study, we first tested whether loss of MBNL2 specifically in 
glutamatergic neurons of the forebrain would be sufficient to provoke 
behavioral and neurochemical alterations associated with DM1, and 
whether MRZ could be a new promising treatment option for suppression 
of brain DM1-like phenotypes. Moreover, we investigated the mechanisms 
of action of MRZ by studying changes in relevant receptors and 
neurotransmitter systems in the mPFC and HPC applying gene expression 
and targeted metabolomics techniques.  
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2. RESULTS 
2.1 MRZ Rescues Pupal Viability in the Drosophila CNS-DM1 model 
In this study, we screened 1200 FDA-approved drugs from the Prestwick 
Chemical Library at the concentrations of 1 and 10 µM. Out of 1200 drugs 
tested, we identified 36 compounds that rescued the female Drosophila 
viability, indicating an anti-DM1 effect (Fig. 1d). These anti-DM1 
compounds belonged to different therapeutic categories such as 
antibacterial (8%), anti-inflammatory (11 %), and others (81 %), which 
included antipsychotics, anticonvulsants and antidepressants. Among the 
antidepressants, MRZ showed potent anti-toxic effects in the 28 ºC assay 
(Fig. 1e), significantly rescuing pupal viability at the doses of 1 µM 
(p<0.01) and 10 µM (p<0.05), with respect to vehicle administration. 
Similarly, in the 29 ºC test (Fig. 1f), MRZ showed significant anti-DM1 
effect at the doses of 0.1 and 1 µM. Due to the multifarious mechanism of 
action of MRZ, different from other antidepressants, its beneficial effects 
could have involved various neurotransmitter receptor targets. Therefore, 
we assessed the anti-DM1 activity of several compounds with different 
pharmacological profiles. Our results show that neither the 5-HT reuptake 
inhibitor fluoxetine, the 5-HT2A receptor antagonists (ritanserin and MDL-
11939), nor the 5-HT3 receptor antagonist, granisetron showed any rescue 
of pupal viability (Fig. 1g). 
 
2.2 Generation of a Tissue-Specific Mouse Model Lacking the Mbnl2 
gene in Glutamatergic Neurons  
Mbnl2 constitutive knockout (KO) mice display a wide range of behavioral 
alterations, including impaired long-term memory, emotional working 
memory and increased depressive-like behavior related to DM1-CNS 
phenotype (Ramon-Duaso et al., 2019). MBNL2 protein is prominently 
expressed in the HPC (Charizanis et al., 2012), where glutamatergic 
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neurons are predominant. In this study, we generated a tissue-specific 
mouse model selectively lacking the Mbnl2 gene in the forebrain 
glutamatergic neurons (Mbnl2NEX-cKO) (Fig. 2a). We confirmed the cell-
specific loss of MBNL2 in excitatory neurons of the forebrain using 
Western blot analysis of brain tissues. One way ANOVA revealed that, in 
brain lysates of Mbnl2NEX-cKO mice, MBNL2 protein levels were reduced by 
90% in the mPFC (WT: 100±5.88, Mbnl2NEX-cKO: 10.39±2.37; F(1,11)= 885.2, 
p<0.001) and by 80% in the HPC (WT: 100±2.26, Mbnl2NEX-cKO: 
19.76±1.48; F(1,11)=199.9, p<0.001)  in comparison with WT mice (Fig. 2b). 
In the striatum and cerebellum, MBNL2 levels were not altered due to the 
low expression of NEX in these brain areas. Moreover, we quantified the 
immunoreactivity of MBNL2 protein by immunofluorescence staining in 
the mPFC and HPC of WT and Mbnl2NEX-cKO. Accordingly, the analysis of 
MBNL2 expression in Mbnl2NEX-cKO mice showed a significant decrease of 
immunoreactivity in the mPFC [F(1,11)=99.0, p<0.001] and HPC 
[F(1,11)=17.5, p<0.001] with respect to WT group (Fig. 2c). 
2.3 Mbnl2
NEX-cKO
 Mice Exhibit Impaired Long-term Recognition 
Memory and Depressive-Like Behavior 
We first performed a battery of behavioral tests in WT (n=10) and 
Mbnl2NEX-cKO (n=10) male mice to assess motor, cognitive and affective 
processes at two time points: 3 and 8 months of age. Total horizontal 
locomotion and number of rearings in the locomotor cages were not 
significantly different between groups (Fig. 3a, b). For long-term 
recognition memory, two-way ANOVA revealed a significant effect of 
genotype [F(1,39)=84.5, p<0.001] and interaction [F(2,39)=4.8, p<0.05], but 
with no significant effect of time. Subsequent post-hoc analysis revealed 
that Mbnl2NEX-cKO mice exhibited a greater cognitive impairment than WT 
mice (p<0.001) at both 3 and 8 months of age (Fig. 3c). For depressive-like 
behavior, two-way ANOVA only revealed a significant main effect of 
RESULTS: ARTICLE 2 
 
 85 
genotype [F(1,39)=102.8, p<0.001], indicating that Mbnl2
NEX-cKO exhibited 
higher immobility time compared to WT at both 3 and 8 months (Fig. 3d). 
These data indicate that the behavioral alterations observed due to loss of 
MBNL2 in glutamatergic neurons of the neocortex and HPC persist in time, 
lasting at least up to 8 months of age.  
 
2.4 Chronic Treatment with MRZ Reduces the Cognitive Deficits and 
Depressive-Like Phenotype in Mbnl2
NEX-cKO
 Mice 
The effects of chronic treatment with MRZ were tested in WT (n=10 per 
group) and Mbnl2NEX-cKO (n=10 per group) male mice at 4 months of age. 
In locomotor activity, no statistical differences were observed in total 
horizontal locomotion or number of rearings (Fig. 4a, b). In the NOR test, 
two-way ANOVA revealed significant main effects of genotype 
[F(1,59)=33.4, p<0.001], treatment [F(2,59)=21.1, p<0.001] and interaction 
between factors were observed [F(2,59)=18.1, p<0.001]. The post-hoc test 
revealed that Mbnl2NEX-cKO mice treated with vehicle displayed cognitive 
deficits in comparison with WT mice (p<0.001), and chronic treatment with 
MRZ significantly reversed this impairment at both doses of MRZ tested 
(p<0.001) (Fig. 4c). In the FST, two-way ANOVA revealed significant 
main effects of genotype [F(1,59)=9.5, p<0.01], treatment [F(2,59)=8.8, 
p<0.001] and interaction between factors were found [F(2,59)=10.6, 
p<0.001]. Subsequent analysis revealed a significant increase in immobility 
time in Mbnl2NEX-cKO mice treated with vehicle with respect to WT controls 
(p<0.001), indicating a depressive-like state, that was attenuated at both 
doses of MRZ (p<0.001) (Fig. 4d). 
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2.5 Mbnl2
NEX-cKO
 Mice Show Increased Neuroinflammation in the DG 
of the HPC and Chronic Treatment with MRZ reverses this Effect 
Microglial expression was evaluated by quantifying the Iba1 marker in the 
mPFC and HPC of WT (n=6 per group) and Mbnl2NEX-cKO (n=6 per group) 
male mice. In the mPFC and CA1 and CA3 fields of the HPC (Fig. 5a-c) 
the number of Iba1 positive cells was not significantly different between 
groups. In contrast, in the DG, two-way ANOVA showed a significant main 
effect of genotype [F(1,35)=18.6, p<0.001], treatment [F(2,35)=18.7, p<0.001] 
and interaction between factors [F(2,35)=5.7, p<0.01] were observed. Further 
analysis revealed a significant increase in microglial expression in 
Mbnl2NEX-cKO mice treated with vehicle compared to WT controls 
(p<0.001), and both doses of MRZ (3 and 10 mg/kg) attenuated this 
overexpression (p<0.001) (Fig. 5d). Moreover, to classify the state of the 
exacerbated microglia in the HPC, we performed a gene expression analysis 
in whole hippocampal lysates, with the pro-inflammatory marker 
interleukin 1 beta (IL-1β) and the anti-inflammatory marker transforming 
growth factor (TGF-β). For expression of IL-1β , two-way ANOVA showed 
a significant main effect of treatment [F(2,35)=7.1, p<0.01] and interaction 
between factors [F(2,35)=7.5, p<0.01]. Post-hoc analysis revealed an increase 
of transcriptional levels of IL-1β in Mbnl2NEX-cKO treated with vehicle with 
respect to WT mice (p<0.01), and both doses of MRZ reversed this 
inflammatory process (p<0.01) (Fig. 5e). However, no significant effects of 
treatment were observed in the gene expression of the anti-inflammatory 
marker TGF- β between groups (Fig. 5f).  
 
2.6 Mbnl2
NEX-cKO
 Mice Exhibit Neuronal Loss in the DG of the HPC 
and MRZ reduces this Effect  
Neuronal expression was evaluated by quantifying the NeuN marker in the 
mPFC and HPC of WT (n=6 per group) and Mbnl2NEX-cKO (n=6 per group) 
male mice. No statistical differences were observed between groups in the 
RESULTS: ARTICLE 2 
87 
mPFC, CA1 and CA3 brain areas (Fig. 6a-c). In contrast, in the DG, two-
way ANOVA revealed a significant interaction between factors [F(2,35)=5.6, 
p<0.01], but  no significant main effect of genotype or treatment. Moreover, 
post-hoc test revealed that vehicle-treated Mbnl2NEX-cKO mice showed a 
significant decrease in the number of NeuN positive cells with respect to 
WT mice (p<0.01) and this effect was reversed with the dose of 10 mg/kg 
of MRZ (p<0.05) (Fig. 6d). Given that exacerbated microglia and neuronal 
loss were mainly observed in the DG, we performed studies of neurogenesis 
and apoptosis, two processes that could be dysregulated in Mbnl2NEX-cKO 
mice. In BrdU immunostaining, although a tendency for less cell 
proliferation in vehicle-treated Mbnl2NEX-cKO mice was observed in 
comparison with WT mice, Two-way ANOVA only revealed a significant 
main effect of treatment [F(2,35)=76.1, p<0.01], but with no main effect of 
genotype or interaction between factors (Fig. 6e) indicating that MRZ 
increased cell proliferation in both genotypes equally. In DCX expression, 
two-way ANOVA showed a significant main effect of treatment 
[F(2,35)=40.6, p<0.001], and interaction between factors [F(2,35)=4.6, p<0.05], 
with no main effect of genotype. Further analysis revealed a significant 
decrease of DCX integrated density in Mbnl2NEX-cKO treated with vehicle 
compared to WT group (p<0.001), indicating a reduction of immature cells 
in Mbnl2NEX-cKO mice. MRZ, however, significantly increased DCX in both 
genotypes to a similar extent (p<0.01) (Fig. 6f). No significant differences 
between groups treated with vehicle were observed in caspase-3 protein 
(data now shown), indicating that there is no deregulation in the cell death 
cycle. 
2.7 MRZ Modulates the Expression of 5-HT1A and H1 Receptors in the 
HPC of Mbnl2
NEX-cKO
 mice 
To gain deeper insight into the neurobiological substrates that underlie the 
behavioral alterations observed in Mbnl2NEX-cKO mice and the mechanisms 
RESULTS: ARTICLE 2 
 
 88 
of action of MRZ, we evaluated the transcriptional activity of 5-HT1A, 5-
HT2A, 5-HT2C, 5-HT3, adrenergic α2A and histamine H1 receptors in the 
mPFC and HPC of WT (n=6 per group) and Mbnl2NEX-cKO (n=6 per group) 
male mice treated chronically with VEH or MRZ (3 and 10 mg/kg). In the 
mPFC, no significant differences were found between treatments in the 
expression levels of serotonin receptors (Fig. 7a-c). However, a main effect 
of genotype was revealed for 5-HT1AR mRNA levels [F(2,35)=24.8, 
p<0.001], indicating a lower expression in Mbnl2NEX-cKO mice (Fig. 7d). For 
alpha2A receptor, a significant interaction was observed between factors 
[F(2,35)=3.0, p<0.05]. Post-hoc analysis revealed decreased levels of alpha2A 
receptor in Mbnl2NEX-cKO mice treated with vehicle as compared with WT 
mice (p<0.05) and no significant differences between genotypes were found 
following MRZ treatment (Fig. 7e). Two-way ANOVA did not reveal any 
significant differences in the histamine H1 receptor (Fig. 7f). In the HPC, 
statistical analysis revealed a significant main effect of genotype for 5-HT2A 
[F(2,35)=5.9, p<0.05] and for 5-HT2C [F(2,35)=8.3, p<0.01] gene expression 
(Fig. 7g, h). The transcriptional levels of 5-HT3 and alpha2A receptors were 
not significantly different between groups (Fig. 7i, k). However, for 5-
HT1AR gene expression, a significant interaction between genotype and 
treatment was observed [F(2,35)=5.8, p<0.01]. Post-hoc comparisons showed 
that 5-HT1AR mRNA levels were significantly decreased in vehicle-treated 
Mbnl2NEX-cKO mice as compared to WT mice (p<0.05), and MRZ reverse 
this effect at the dose of 10 mg/kg (p<0.001) (Fig. 7j). For the 
transcriptional levels of histaminergic H1 receptor, a significant main effect 
of genotype [F(2,35)=5.1, p<0.05] and a significant interaction between 
genotype and treatment [F(2,35)=12.2, p<0.001] were found. Subsequent 
analysis showed a significant increase of H1 levels in Mbnl2
NEX-cKO mice 
treated with vehicle as compared to WT group (p<0.001), and MRZ reverse 
this effect at the dose of 3 mg/kg (p<0.01) and 10 mg/kg (p<0.001) (Fig. 
7l). 
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2.8 MRZ Modulates Monoamine, GABA and Adenosine production in 
the HPC of Mbnl2
NEX-cKO
 mice 
To further examine possible alterations in neurotransmitter systems, we 
performed targeted metabolomics studies after chronic treatment (21 days) 
with vehicle or MRZ (3 and 10 mg/kg) in brain homogenates of mPFC and 
HPC of WT (n=6 per group) and Mbnl2NEX-cKO (n=6 per group) male mice. 
We determined the tryptophan (Trp) and tyrosine (Tyr) metabolism in order 
to quantify the generation of 5-HT and NA neurotransmitters, as well as, 
the generation of GABA, Glu, and adenosine neurotransmitters.  
We quantified the ratio of 5-HT/Trp as a measure of 5-HT production, and 
in the mPFC, statistical analysis revealed a significant interaction between 
factors [F(2,30)=4.2, p<0.05], but no significant main effects of genotype or 
treatment. Post-hoc analysis showed that chronic treatment with 10 mg/kg 
of MRZ significantly reduced the generation of 5-HT in WT mice compared 
to those treated with vehicle (p<0.001) (Fig. 8a). In contrast, in the HPC, 
two-way ANOVA showed a significant interaction in the ratio 5-HT/Trp 
[F(2,30)=6.4, p<0.01]. Subsequent analysis exhibited a significant decrease 
in the production of 5-HT from its precursor Trp in Mbnl2NEX-cKO mice 
treated with vehicle compared to WT mice (p<0.05). Moreover, MRZ at 10 
mg/kg significantly reduced the generation of 5-HT in WT mice in 
comparison with WT group treated with vehicle (p<0.05) (Fig. 8f). No 
significant differences were observed when considering 5-HT degradation 
(5-HIAA/5-HT) (Data not shown). 
We quantified the ratio of NA/Tyr as a measure of NA production, and the 
statistical analysis in the mPFC showed a significant interaction between 
factors [F(2,30)=5.4, p<0.05] with a significant decrease of NA production in 
Mbnl2NEX-cKO mice treated with vehicle compared to WT mice (p<0.05) 
while MRZ at 10 mg/kg significantly reduced the generation of NA in WT 
mice compared to WT group (p<0.05) (Fig. 8b). In the HPC, two-way 
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ANOVA revealed a significant main effect of genotype [F(1,30)=17.9, 
p<0.001] and interaction between factors [F(2,30)=5.9, p<0.01]. Post-hoc 
analysis showed an increase in NA production in Mbnl2NEX-cKO mice treated 
with MRZ at 10 mg/kg in comparison with WT group (p<0.001), while this 
dose of MRZ reduced the production of NA in the WT group in comparison 
with WT mice treated with vehicle (p<0.05) (Fig. 8g). ). No significant 
differences were observed when considering NA degradation (NE/NA) 
(Data not shown). 
We quantified the ratio of GABA/Glu as a measure of GABA production, 
and the statistical analysis in the mPFC did not expose significant 
differences between groups (Fig. 8c). In contrast, in the HPC, a significant 
interaction between factors was found [F(2,30)=4.8, p<0.05]. Subsequent 
analysis revealed a significant increase of GABA production in Mbnl2NEX-
cKO mice treated with MRZ 10 mg/kg in comparison with Mbnl2NEX-cKO mice 
treated with vehicle (p<0.05) (Fig. 8h). 
We also determined the ratio of Glu/Gln as a measure of Glu production 
and statistical analysis only showed a significant main effect of genotype in 
mPFC [F(1,30)=5.0, p<0.05] and HPC [F(1,30)=28.3, p<0.001], indicating that 
Mbnl2NEX-cKO mice had lower generation of Glu compared to WT 
group.(Fig 8d, i). The statistical analysis of adenosine concentrations 
showed a main effect of genotype [F(1,30)=4.4, p<0.05] in the mPFC due to 
an increase in WT mice treated with 10 mg/kg of MRZ, with no main effect 
of treatment or interaction between factors (Fig. 8e). In the HPC, a 
significant interaction was found [F(2,30)=4.4, p<0.05], with no main effects 
of genotype or treatment. Post-hoc analysis revealed a significant reduction 
of adenosine levels in Mbnl2NEX-cKO mice treated with vehicle in comparison 
with WT group (p<0.05) and the dose of 10 mg/kg of MRZ reversed this 
effect (p<0.05) (Fig. 8j). 
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3. DISCUSSION 
Our previous work demonstrated that constitutive deletion of Mbnl2 in mice 
resulted in cognitive impairments and depressive-like behavior, that 
persisted up to 5 months of age, and recapitulated the neuropsychological 
disturbances observed in DM1 (Ramon-Duaso et al., 2019). The present 
findings reveal that conditional loss of the Mbnl2 gene specifically in 
forebrain glutamatergic neurons of the PFC and HPC provoked: (i) long-
lasting DM1-related behavioral disturbances, and (ii) neuronal and glial 
alterations in the DG and receptor/neurotransmitter changes in the HPC.   
Accordingly, deregulation of neural networks between mPFC and HPC has 
been shown to occur in DM1 patients (Romeo et al., 2010), and is 
associated to alterations in cognition and affective functions (Sampath et 
al., 2017; Richardson and Adams, 2018). Several clinical studies have 
shown that most patients with depression, including DM1 patients 
(Nätterlund and Ahlström, 2001), report significant deficits in executive 
function, memory and attention (Russo et al., 2015; Kaser et al., 2017). 
Although both cognitive dysfunction and depression represent a major 
burden for patients and family, there are no medications currently approved 
for treating the complex CNS symptomatology seen in DM1 patients.   
Our in vivo screening results in a transgenic Drosophila showed that the 
atypical antidepressant, MRZ was able to rescue female pupal viability, 
suggesting anti-CNS-related toxicity in this DM1 fly model. To explore the 
mechanisms of action of MRZ, we treated flies with compounds known to 
be targets of MRZ. The results revealed that neither the SSRI, fluoxetine 
nor the 5-HT2AR antagonists (ritanserin and MDL-11939), or the 5-HT3R 
antagonist, granisetron induced anti-toxicity effects when tested 
individually. These findings suggested that the effects of MRZ could be due 
to a combinatory action on all of these targets, or on other neurotransmitter 
receptors that were not tested in the assay. Therefore, we examined the 
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effects of MRZ on the behavioral and neurochemical alterations observed 
in the Mbnl2NEX-cKO mouse model, selecting two low doses (3 and 10 mg/kg) 
from our pilot study that did not reduce locomotor activity in WT mice, to 
ensure the lack of confounding sedative effects in our behavioral studies. 
Indeed, some clinical trials have shown that small doses of MRZ may 
induce excessive sedation, while other studies have not reported this effect 
(Anttila and Leinonen, 2001). Our data in Mbnl2NEX-cKO mice showed that 
MRZ reversed both cognitive impairment and depressive-like behavior 
without affecting locomotor activity.  
The behavioral changes in Mbnl2NEX-cKO mice were associated with 
exacerbated microglia expression specifically in the DG of the HPC in 
comparison with WT mice. Moreover, the transcriptional levels of the pro-
inflammatory cytokine, IL-1β, were enhanced in the HPC of these mice, 
while no alterations were found in the gene expression of TGF-β, an anti-
inflammatory cytokine. Interestingly, previous studies have reported a 
microglia enhancement in DM1 brains (Satoh et al., 2016), attributable to a 
high prevalence of white matter damage in this disease (Itoh et al., 2010). 
In addition to increased microgliosis, Mbnl2NEX-cKO mice exhibited 
significant neuronal loss, decreased neurogenesis, and significantly fewer 
proliferating and immature neurons in the DG of the HPC. These findings 
are consistent with the diffuse brain damage observed in DM1 patients 
(Mizukami et al., 1999; Itoh et al., 2010; Takado et al., 2015), and with the 
data showing that both depression and cognitive deficits are related to 
altered neurogenesis in the HPC (Cao et al., 2004; Papakostas and 
Culpepper, 2015). While the behavioral alterations observed in the tissue-
specific Mbnl2NEX-cKO model are similar to those observed in constitutive 
Mbnl2 mice (Ramon-Duaso et al., 2019), the associated changes in neuronal 
and glial cells show several differences in both models. Hence, in the 
constitutive KO we observed more extended microgliosis, including the 
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mPFC and the entire HPC, but no neuronal loss. In the conditional KO 
however, microgliosis was restricted to the DG of the HPC, where neuronal 
loss was also present. These findings imply that loss of MBNL2 
constitutively induces more wide-spread brain inflammation than a tissue-
specific deletion in glutamatergic neurons. Moreover, the specific effects 
observed in the DG indicate that this structure is particularly sensitive to 
the lack of MBNL2 protein, leading to the observed behavioral deficits. In 
accordance, studies in rats have demonstrated that the DG is required to 
mediate pattern separation (Kesner et al., 2004), a central mechanism for 
novelty detection within an environment and for learning and memory 
(Bakker et al., 2008). In fact, it has been described that DG-lesioned rats 
are not able to discriminate between the familiar and novel object 
(Hunsaker et al., 2008). Also, impaired adult neurogenesis in the DG has 
been related to depressive states (Jacobs et al., 2000). Overall, our data 
reveal that lack of MBNL2 protein in the DG (inducing neuronal loss, 
decreased neurogenesis, and inflammatory microglia activation) is 
sufficient to cause cognitive deficits and depression-like behavior. 
Notably, chronic treatment with MRZ attenuated microglial and pro-
inflammatory cytokine overexpression, and neuronal loss in Mbnl2NEX-cKO 
mice, and increased neurogenesis in the DG of WT and Mbnl2NEX-cKO mice. 
Thus, by restoring neuronal and glial function in the DG of the HPC, MRZ 
may reverse the depressive-like behavior and cognitive impairment in 
Mbnl2NEX-cKO mice. In accordance, cellular adaptations in the HPC after 
repeated antidepressant administration have been shown to play an 
important role in their behavioral effects (Malberg et al., 2000; Santarelli et 
al., 2003). Moreover, chronic treatment with MRZ decreases plasma levels 
of pro-inflammatory markers in depressed patients (Tulner et al., 2011), and 
reestablishes the equilibrium between physiological and pathological levels 
of cytokines in the brain (Müller and Schwarz, 2007; Sutcigil et al., 2007).  
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Since loss of MBNL2 protein in forebrain glutamatergic neurons lead to 
neuronal loss and microglia enhancement in Mbnl2NEX-cKO mice, we next 
investigated more specifically which types of neuronal receptors and 
neurotransmitters were altered, and whether MRZ administration could 
reverse these changes. In the first place, we examined the expression 
changes of serotonergic, noradrenergic, and histaminergic receptors, which 
are known targets of MRZ. Our data showed a significant reduction in 5-
HT1AR gene expression, and an increase in H1R transcriptional levels 
specifically in the HPC of Mbnl2NEX-cKO mice treated with vehicle. 
Decreased 5-HT1AR gene transcription in these mice could be related to 
neuronal loss found in the HPC, where they are highly expressed. 
Moreover, these receptors are crucially involved in depression, anxiety and 
memory processes (Le François et al., 2008). On the other hand, an increase 
in H1R may be associated to inflammatory processes, since these receptors 
contribute to the effects of histamine on microglial activation following 
neural death (Rocha et al., 2016). Interestingly, MRZ increased 5-HT1AR 
and reduced H1R gene expression in the HPC of Mbnl2
NEX-cKO mice. Thus, 
the neuroprotective effects of MRZ in the HPC of Mbnl2NEX-cKO mice may 
be due to a reduction in microglia activation through its action on H1R.   
Secondly, we determined changes in the production of brain 
neurotransmitters and their metabolites in HPC and mPFC homogenates 
using targeted metabolomics. We found that Mbnl2NEX-cKO mice treated with 
vehicle presented a significantly lower production of 5-HT and adenosine 
in the HPC. Accordingly, loss of 5-HT neurons has been reported in DM1 
patients (Ono et al., 1998b). As expected by its mechanisms of action, 
chronic treatment with MRZ at 10 mg/kg increased 5-HT and NA 
production (Anttila and Leinonen, 2001). Interestingly, we also found that 
this dose of MRZ increased GABA and adenosine production in the HPC 
of Mbnl2NEX-cKO mice. This result is in line with previous studies showing 
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that MRZ increases GABA and reduces Glu concentrations in nucleus 
accumbens homogenates in a rat model of chronic mild stress (Kamal et al., 
2013). While no evidence is currently available as to the effects of MRZ on 
adenosine neurotransmission, our data suggests that this compound may be 
increasing adenosine in the HPC to modulate neuronal and glial stability. 
Indeed, adenosine acting on A1 receptors reduces excitatory transmission, 
and is neuroprotective in brain injuries (Ribeiro et al., 2003).  
Together, these data reveal that the beneficial effects of MRZ may be 
associated with re-establishing receptor function in known targets, such as 
5HT1AR and H1R, and also by alternative mechanisms involving GABA 
and adenosine neurotransmission in the HPC 
In conclusion, using the Mbnl2NEX-cKO mouse model we revealed that 
granule cells of the DG and surrounding glial cells are markedly sensitive 
to loss of MBNL2 protein leading to brain-related DM1 impairments. These 
results provide new insights into the neurobiological mechanisms related to 
brain phenotypes in DM1. In addition, we provide evidence that MRZ could 
be a potential new treatment to counteract the neurodegenerative process, 
and the cognitive and affective disorders observed in DM1, through a 
mechanism of action involving known targets, such as 5-HT and 
histaminergic receptors, but also through a novel mechanism of action 
involving GABA and adenosine neurotransmission.  
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4. MATERIALS AND METHODS 
4.1 Drosophila Transgenes 
The Drosophila mushroom body-Gal4 (MB-Gal4) line (Tettamanti et al., 
1997) was obtained from Dr. J.D. Armstrong (Institute of Biomedical and 
Life Sciences, University of Glasgow, United Kingdom) and the yw line 
was obtained from Bloomington Drosophila Stock Center (Indiana 
University). The recombinant lines yw; +; UAS-CTG480 and yw; +; UAS-
CTG480 UAS-GFP are described in Garcia-Lopez et al. 2008. Flies were 
maintained at 25 ºC on standard nutritive medium unless stated otherwise. 
X chromosome-linked targeted expression of 480 CTG repeats to the 
mushroom bodies (MB) originates a temperature-sensitive viability 
phenotype that affects only females while males serve as an internal control 
(Fig. 1a-c). Thus, at 29 ºC no adult females hatch from the pupa whereas at 
28 ºC a small percentage of females are able to emerge (Garcia-Lopez 
2008). We used this DM1 fly model to identify drugs that significantly 
modify CUG repeat-induced toxicity as candidate therapies against DM1. 
 
4.2 Generation of Conditional Mbnl2 Knock-out Mice (Mbnl2
NEX-cKO
) 
To induce a tissue-specific deletion of Mbnl2 gene in forebrain 
glutamatergic neurons, Mbnl2fl/fl conditional mice (kindly provided by Dr. 
M. Swanson, University of Florida) were crossed with mice expressing a 
Cre recombinase under the neuronal differentiation 6 (NeuroD6) gene 
promoter (also known as NEX: kindly provided by Dr. K. Nave, Max 
Planck Institute) (see Suppl. Fig.S1). NEX-Cre transgene mice (Goebbels 
et al., 2006) were kindly shared by Klaus-Armin Nave (Max Planck 
Institute of Experimental Medicine, Göttingen, Germany). Each breeding 
cage consisted of two homozygous female mice (genotype: Mbnl2fl/fl) with 
one hemizygous male mouse (genotype: Cre+/-). Mice were genotyped 
using a PCR-based strategy to detect the presence of the LoxP flanked allele 
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and the integration of the Cre transgene. The genotyping primers are shown 
in Supplementary Table S1. Mice were bred in the animal facilities of the 
PRBB to generate WT and Mbnl2NEX-cKO littermates. All mice were 
grouped-housed and maintained in a temperature (21 ± 1°C) and humidity 
(50 ± 10%) controlled environment in a room with a 12 h light/dark cycle 
(lights on at 8 am and off at 8 pm) with food and water available ad libitum. 
All the behavioral experiments were performed during the light phase of 
the light/dark cycle by a trained observer that was blind to experimental 
conditions. Animal procedures were adhered to the standard guidelines of 
the National Institutes of Health 1995; European Communities Directive 
(86/609 EEC) and approved by the local ethical committee (CEEA-PRBB). 
After behavioral assessment, mice were euthanized by cervical dislocation 
to obtain brain areas for western blot, quantitative PCR and targeted 
metabolomics or transcardial perfused for immunohistochemical analysis. 
For the timeline of experimental procedures see Supplementary Figure S2. 
 
4.3 Drugs and treatments 
Drosophila in vivo drug screening was performed as follows: two yw;+ ; 
UAS-CTG480 females were crossed with one MB-Gal4 male and placed in 
vials containing nutritive media supplemented with the compounds from 
the Prestwick Chemical Library (PCL; 1200 compounds) 
(http://www.prestwickchemical.com/libraries-screening-lib-pcl.html) at 1 
µM final concentration. The crosses were cultured for two days at 25ºC in 
96-well trays, where the first column contained vials of the control crosses 
(two yw females and one MB-Gal4 male) and the twelfth column was for 
crossings of two yw; +; UAS-CTG480 females and one MB-Gal4 male 
treated with vehicle (DMSO). Offspring were shifted to 28 or 29 ºC till 
hatching and the number and sex of F1 adult progeny was scored. 
Compounds were tested per triplicate and those showing the capacity to 
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rescue any female viability at 29 ºC were considered primary hits. Males 
were used as internal controls to discard toxic drugs. 
 
MRZ (Alomone Labs) of a purity of 99.5% was dissolved in a vehicle 
solution (5% DMSO, 5% Tween80 and 90% saline) and administered 
intraperitoneally (i.p.) in a volume of 0.1 ml/10 g of body weight. To 
determine the optimal doses of MRZ to be used for chronic administration, 
we first carried out a dose-response curve in locomotor studies. Male WT 
and Mbnl2NEX-cKO littermates were treated once daily and during 5 
consecutive days with vehicle (VEH) or 1, 3, 10 and 30 mg/kg of MRZ. 
Thus, we evaluated the effects of acute (after a single administration) and 
subchronic (after following 5 days) treatment by placing the mice in the 
locomotor cages during 1 hour. At both time points, only the highest dose 
of MRZ, 30 mg/kg, significantly reduced the locomotor activity in 
comparison with VEH administration (See Supplementary figure S2). Thus, 
to avoid the sedative effects of the drug, WT and Mbnl2NEX-cKO were treated 
with VEH or MRZ (3 and 10 mg/kg) once daily for 21 days. See 
Supplementary Figure S2 for a timeline of experimental procedures. 
 
4.4 Behavioral assessment  
4.4.1 Locomotor activity assessment 
To evaluate locomotor responses in WT and Mbnl2NEX-cKO male mice, mice 
were tested in individual locomotor boxes (9 x 20 x 11 cm; Imetronic, 
Bordeaux, France) equipped with two lines of infrared beams in low-
lighting conditions (20 lux). Total horizontal activity and the number of 
rearings (standing on rear limbs) were analyzed during a 30 min-period. 
4.4.2 Novel Object Recognition (NOR) 
Long-term recognition memory was assessed using the novel object 
recognition (NOR) test with the V-maze at 15 lux as previously described 
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(Busquets-Garcia et al., 2013). Briefly, this test consists of 3 phases of 9 
min each (habituation, familiarization and test). The first day, mice were 
habituated to the empty maze. The second day, mice were placed again in 
the maze and 2 identical objects were presented. Twenty-four hours later, 
one of the familiar objects was replaced with a novel object and the time 
exploring both objects (novel and familiar) was measured. Object 
exploration was defined as the orientation of the nose towards the object 
and touching it with the nose. A discrimination index (DI) was used as 
outcome of cognitive behavior. A higher DI score represents a greater 
recognition memory.  
 
4.4.3 Forced Swim Test (FST) 
Depressive-like behavior was evaluated using the forced swim test (FST) 
(Porsolt et al., 1977). Briefly, mice were placed for 6 min into a transparent 
Plexiglas cylinder filled with water (24 ± 1°C), and the total immobility 
time was measured for the last 4 min of the test. Immobility was considered 
when the animal made no movements to escape. An increase in immobility 
is associated with a higher depressive-like state. 
 
4.5 Western blotting 
To validate the strategy of the tissue-specific Mbnl2NEX-cKO mouse line, we 
performed western blots in cortical, hippocampal, striatal and cerebellar 
brain areas to quantify the MBNL2 protein. A general immunoblot analysis 
was followed as previously described (Abad et al., 2019). Briefly, to extract 
total protein, tissues were dounce-homogenized at 4ºC in 30 volumes of 
RIPA buffer (Roche Diagnostics, Barcelona, Spain). Equal amounts of 
protein (40 μg) were loaded onto a 10% acrylamide gel and transferred to 
Immobilion-P PVDF sheets (Millipore, Darmstadt, Germany). Membranes 
were blocked for 1h at room temperature with 5% skimmed milk and 
incubated 2 h at room temperature with mouse anti-Mbnl2 (1:500, Sta. Cruz 
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Technologies; sc-136167). Then, membranes were incubated with the 
corresponding secondary antibody mouse anti-GAPDH (1:5.000, Sta. Cruz 
Technologies; sc-32233). The detection was visualized by 
chemiluminescence ChemiDoc XRS methodology and protein expression 
levels were quantified by QuantityOne software (Bio-Rad, Madrid, Spain). 
The optical density of the bands was normalized to the amount of 
housekeeping control GAPDH and expressed as a percentage of control. 
The whole list of antibodies used in these experiments is shown in 
Supplementary Table S2. 
 
4.6 Immunofluorescence studies  
Forty-eight hours after the behavioral assessment, mice were anesthetized 
by an i.p. injection of a mixture of ketamine (100 mg/kg) and xylazine (20 
mg/kg) and transcardially perfused with 4% paraformaldehyde. Coronal 
sections of 30 µm containing the cingulate, prelimbic and infralimbic areas 
of the mPFC (from bregma +2.71 to +1.70 mm) and the CA1, CA3 and 
dentate gyrus (DG) of the HPC (from bregma -1.22 to -2.46 mm) were 
obtained using a cryostat (Leica CM3050 S). The expression of ionized 
calcium binding adapter molecule 1 (Iba1) and neuron specific nuclear 
protein (NeuN) was determined by immunofluorescence studies as 
described previously (Ramon-Duaso et al., 2019). The primary and 
secondary antibodies used are list in Supplementary Table S2. Moreover, 
to analyze proliferation-related markers, we used 5-bromo-2’-deoxyuridine 
(BrdU) to label the proliferating population that incorporated BrdU during 
the S phase of the cell cycle and the microtubule-associated protein 
doublecortin (DCX) to label immature neurons (up to four weeks), which 
may have started to develop a differentiated neuronal morphology (Luján 
et al., 2018). For BrdU labeling, mice were treated with a single i.p. 
injection of BrdU at the dose of 100 mg/kg (Sigma, St.Louis, MO) after 
chronic treatment with MRZ and behavioral assessment. For experimental 
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procedures see Supplementary Figure S2. A DNA denaturation step in 2 M 
HCl for 15 minutes at 37ºC was required only for BrdU staining (Wojtowicz 
and Kee, 2006). Images were obtained using a Nikon Eclipse Ni-E 
microscope. Six to eight representative images from each mouse were 
analyzed defining a region of interest (ROI) that remained constant in all 
experimental groups. All images were processed using the ImageJ software 
(NIH). The quantification of BrdU and DCX positive cells from the 
subgranular zone (SGZ) of the HPC was performed as previously described 
(Saravia et al., 2019). 
 
4.7 Quantitative Real-Time PCR analysis  
We determined the transcriptional levels of several neurotransmitter 
receptors, including 5-HT1A, 5-HT2A, 5-HT2C, 5-HT3, adrenergic α2A and 
histamine H1. This procedure was performed as previously described 
(Duart-Castells et al., 2018) with minor modifications. Total RNA isolation 
was carried out by RNeasy Mini Kit (Tissue; QIAGEN) and 300 ng of each 
sample was reverse-transcribed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to the manufacturer’s 
instructions. Real-time PCR was performed using the PowerUp SYBR 
Green Master Mix and analyzed by QuantStudio™ 12K Sequence 
Detection System (Applied Biosystems). Primers used are listed in 
Supplemental Table S3. mRNA expression was normalized to the relative 
expression value of β-actin, as endogenous housekeeping gene. Gene 
expression was determined using the comparative cycle threshold (Ct) 
method and the results are reported as fold change compared with the 
control. 
4.8 Metabolomics by LC-MS/MS 
For the targeted metabolomics study, we used brain homogenates from the 
mPFC and HPC of WT and Mbnl2NEX-cKO male mice that had been treated 
chronically with vehicle, MRZ 3 and 10 mg/kg during 21 days. We applied 
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two previously reported methods focused on the quantification of 
neurotransmitters and related compounds in mice brain homogenates. 
Forty-eight hours after the behavioral assessment, a group of mice were 
sacrificed, and polar neurotransmitters (GABA, glutamate, and adenosine) 
were determined as previously described (Olesti et al., 2019a). Given the 
short half-life of monoamines (Cransac et al., 1996), another group of mice 
was sacrificed 1 hour after the last vehicle or MRZ (3 mg/kg and 10 mg/kg 
during 21 days) administration, and the production of NA and 5-HT was 
assessed (Olesti et al., 2019b). For analysis of polar neurotransmitters, an 
aliquot of 10 µL of brain homogenate was transferred into a glass tube and 
was spiked with 50 µL of the internal standard mixture. Then, 130 µL of 
acetonitrile were added to precipitate the proteins. After centrifugation (5 
min; 4000 rpm; 2650 g) the supernatant was transferred to a microvial and 
directly injected into the liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) system. A 1:100 dilution was required for the analysis of 
GABA, glutamine (Gln), glutamate (Glu) and adenosine. For the analysis 
of monoamines, an aliquot of 200 µL of HPC or mPFC was transferred into 
a glass tube, was spiked with 100 µL of internal standard mixture, and was 
dried under nitrogen gas. Then, it was reconstituted with 50 µL of NaHCO3 
100 mM buffer (pH = 10.5) and was derivatized using 100 µL of dansyl 
chloride solution (1 mg/mL in acetone; 60ºC; 20 min). The solvent was then 
transferred to a microvial and was directly injected into the LC-MS/MS 
system. In both methods, the LC-MS/MS system consisted on an Acquity 
UPLC system (Waters Associates) for the chromatographic separation 
coupled to a triple quadrupole (Xevo TQ-S micro) mass spectrometer 
provided with an orthogonal Z-spray-electrospray interface (ESI) (Waters 
Associates, Milford, MA, USA). Analytes were determined by a Selected 
Reaction Monitoring (SRM) method by acquiring two transitions for each 
compound. Besides the response of the analytes, ratios between selected 
metabolites were also considered in order to evaluate not only the levels of 
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neurotransmitters, but also their formation and degradation. As an example, 
the ratio 5-HT/Trp was selected as indicative of 5-HT biosynthesis whereas 
the ratio 5-HIAA/5-HT was considered for the evaluation of 5-HT 
degradation. MassLynx software V4.1 and TargetLynx XS were used for 
data management.  
 
4.9 Statistical Analysis 
In Drosophila studies, in vivo drug screening at 28 ºC was analyzed using 
Fisher’s exact test, in which it was assumed that the number of males is 
equal to the expected number of females in case the rescue was complete. 
One-way ANOVA was used to confirm the specific depletion of the Mbnl2 
gene in the generation of the new tissue-specific mouse line. Two-way 
ANOVA was used to analyze the behavioral data with genotype (WT and 
Mbnl2NEX-cKO) as a between-subjects factor, and age (3 and 8 months of age) 
as a within-subjects factor. The effects of chronic treatment with MRZ were 
analyzed using 2-way ANOVAs with genotype and dose as between-
subject factors. Subsequent Bonferroni’s Post-hoc test was used when 
required. All data were analyzed using SPSS and GraphPAD Prism 8.0 
software. Comparisons were statistically significant when the level of 
significance was p<0.05. 
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FIGURE LEGENDS 
Figure 1. In vivo drug screening using the MB-Gal4 Drosophila line. (a) 
Representative images of control males, expressing no repeats in the 
mushroom bodies (MB) and emerging from pupae (normal fly). DM1 
females are unable to completely emerge from the pupal stage (minus 
compound). DM1 females rescued by the oral administration of defined 
drugs (plus compound). (b) Confocal image of the MB structure marked by 
GFP reporter under the control of MB-Gal4 driver (green) and a graphical 
representation of the left lobe of the MBs. (c) 96-well trays were used for 
the screening of 1200 compounds. (d) Compounds showing anti-DM1 
effects in the Drosophila model: the table indicates the number of hits from 
each therapeutic group. Pharmacological studies with mirtazapine (MRZ) 
at different concentrations: the number of adults which emerged from pupae 
with standard nutritive media supplemented with DMSO (control) or with 
the indicated concentrations of MRZ.  (e) At 28 ºC in the control DMSO 
treatment, a small percentage of females were able to emerge (n=15), 
whereas following MRZ (1 and 10 µM) an increase in female offspring was 
detected (n=20 and n=14, respectively). (f) At 29 ºC, no female pupae 
hatched in the non-treated group, while MRZ (0.1 and 1 µM) rescued at 
least 1 adult female. (g) The atypical antidepressant MRZ, with a 
multimodal activity, had anti-DM1 activity, while closely related 
compounds with different pharmacological profiles did not show a 
significant rescue. Hit compounds were required to score at least 5 males in 
each of the 3 replicates to discard toxicity issues. * p<0.05, ** p<0.01 
(Fisher’s Exact test). 
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Figure 2. Generation and validation of conditional knock-out strategy 
of Mbnl2
NEX-cKO
 mice. (a) Generation of conditional Mbnl2NEX-cKO mouse 
line. On the right, expression pattern of NEX-Cre promoter. (b) Western 
blot analysis of MBNL2 protein levels in the mPFC, HPC, striatum and 
cerebellum in WT (n=6) and Mbnl2NEX-cKO (n=6) mice. The panels on the 
right represent the bands of relative intensity of MBNL2 (upper) and 
GAPDH (lower) used as a loading control. (c) Quantification of MBNL2 
immunoreactivity in the PFC and HPC of WT (n=6) and Mbnl2NEX-cKO 
(n=6) mice. The panels on the right show representative images of MBNL2 
intensity (green). Scale bar=500 µm. Images were taken at x4 
magnification. Values are the mean + SEM. *** p<0.001 vs. WT group 
(one-way ANOVA). 
 
Figure 3. Behavioral assessment of motor, cognitive and depression-
like state in male WT and Mbnl2
NEX-cKO 
mice at 3 and 8 months of age. 
No significant alterations were observed between groups in locomotor 
activity by determining (a) horizontal locomotion and (b) number of 
rearings. (c) Long-term recognition memory was impaired in the Mbnl2NEX-
cKO mice, showing lower rates of discrimination index at 3 and 8 months of 
age compared to WT mice. (d) Depressive-like state was increased in 
Mbnl2NEX-cKO mice, presenting greater immobility times at 3 and 8 months 
of age than WT mice. Values are the mean + SEM. *** p<0.001 vs. WT 
group (2-way ANOVA followed by Bonferroni’s post-hoc analysis). $$$ 
p<0.001 (main effect of genotype). 
 
Figure 4. Behavioral assessment of motor, cognitive and depression-
like state at 5 months of age following the chronic treatment with 
mirtazapine (MRZ). WT (n=10 per group) and Mbnl2NEX-cKO (n=10 per 
group) mice were treated during 21 days with vehicle, 3 and 10 mg/kg of 
MRZ, and behavioral testing was performed one week after the last 
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administration. No statistical differences were observed in locomotor 
activity by determining (a) horizontal locomotion and (b) number of 
rearings. (c) The discrimination index was decreased in Mbnl2NEX-cKO mice 
treated with vehicle and both doses of MRZ reversed this cognitive 
impairment. (d) Immobility time was increased in Mbnl2NEX-cKO mice 
treated with vehicle and both doses of MRZ attenuated this depressive-like 
state. Values are the mean + SEM. *** p<0.001 vs. WT group (genotype 
effect). ### p<0.001 vs. VEH of same genotype (treatment effect) (2-way 
ANOVA followed by Bonferroni’s post-hoc analysis). 
 
Figure 5. Chronic treatment with mirtazapine (MRZ) attenuates the 
enhanced microglial phenotype in the hippocampus (HPC) of 
Mbnl2
NEX-cKO 
mice. Quantification of Iba1 immunofluorescence in WT 
(n=6 per group) and Mbnl2NEX-cKO (n=6 per group) mice. No statistical 
differences were observed in microglial expression in the (a) mPFC, (b) 
CA1 and (c) CA3 regions of the HPC. (d) In the dentate gyrus (DG), an 
enhanced microglial expression was found in Mbnl2NEX-cKO treated with 
vehicle and both doses of MRZ attenuated this overexpression. The 
transcriptional levels of (e) interleukin 1 beta (IL-1β), a pro-inflammatory 
cytokine, were exacerbated in Mbnl2NEX-cKO treated with vehicle and both 
doses of MRZ reversed this cytokine production, whereas no differences 
were observed between groups in the gene expression of (f) transforming 
growth factor (TGF- β), an anti-inflammatory cytokine. The Y-axis shows 
the mRNA expression as a fold change compared with the control group 
(WT VEH). On the bottom, representative images of Iba1 positive cells 
(red) and DAPI counterstaining (blue) of the DG region. Scale bar = 200 
µm. Values are the mean + SEM. * p<0.05, *** p<0.001 vs. WT group 
(genotype effect). ## p<0.01, ### p<0.001 vs. VEH of same genotype 
(treatment effect) (2-way ANOVA followed by Bonferroni’s post-hoc 
analysis). 
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Figure 6. Chronic treatment with mirtazapine (MRZ) reverses the 
neuronal loss in the hippocampus (HPC) of Mbnl2
NEX-cKO 
mice. 
Quantification of NeuN immunostaining in WT (n=6 per group) and 
Mbnl2NEX-cKO (n=6 per group) mice. No statistical differences were 
observed in neuronal expression in the (a) mPFC, (b) CA1 and (c) CA3 
regions of the HPC. (d) In the dentate gyrus (DG), a significant decrease in 
NeuN positive cells was found in Mbnl2NEX-cKO treated with vehicle, and 
the dose of 10 mg/kg of MRZ reversed this neuronal loss. On the right, 
representative images of NeuN positive cells (green). Scale bar = 200 µm. 
Adult neurogenesis was assessed in the subgranular zone (SGZ) of the HPC 
by (e) cell proliferation where MRZ increased the number of BrdU positive 
cells in WT and Mbnl2NEX-cKO mice and by (f) doublecortin (DCX) 
expression where Mbnl2NEX-cKO treated with vehicle exhibited a decrease in 
DCX integrated density, and MRZ increased this immature neuronal 
expression in WT and Mbnl2NEX-cKO mice. On the bottom, representative 
images of BrdU positive cells (green dots) and DCX positive cells (red 
marker). Values are the mean + SEM. **p<0.01, ***p<0.001 vs. WT group 
(genotype effect). #p<0.05, ##p<0.01, ###p<0.001 vs. VEH of same 
genotype (treatment effect). +++ (main effect of treatment). (2-way 
ANOVA followed by Bonferroni’s post-hoc analysis).  
 
Figure 7. Chronic treatment with mirtazapine (MRZ) modulates the 
expression of 5-HT1A and H1 receptors in the hippocampus (HPC) of 
Mbnl2
NEX-cKO
 mice. Transcriptional levels of MRZ receptor targets were 
evaluated in WT (n=6 per group) and Mbnl2NEX-cKO (n=6 per group) mice. 
In mPFC, no significant differences were observed in the gene expression 
of (a) 5-HT2A, (b) 5-HT2C and (c) 5-HT3 serotonin receptors. The 
transcriptional levels of (d) 5-HT1A receptor were reduced in all treatment 
groups of Mbnl2NEX-cKO compared to WT groups. Decreased levels of (e) 
alpha2A receptor were revealed in Mbnl2
NEX-cKO mice treated with vehicle 
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as compared with WT mice. (f) Histaminergic H1 receptor was not altered 
in any experimental condition. In the HPC, a main effect of genotype 
between WT and Mbnl2NEX-cKO mice was found in the gene expression of 
(g) 5-HT2A and (h) 5-HT2C serotonin receptors. No significant differences 
between groups were observed in the transcriptional levels of (i) 5-HT3 and 
(k) alpha2A receptors. Importantly, (j) 5-HT1A receptor was significantly 
reduced in the Mbnl2NEX-cKO mice treated with vehicle, and the dose of 10 
mg/kg of MRZ increased its expression. Moreover, the (l) histaminergic H1 
receptor was exacerbated in the Mbnl2NEX-cKO mice treated with vehicle, and 
both doses of MRZ attenuated this expression. The Y-axis shows the 
mRNA expression as a fold change compared with the control group (WT 
VEH). Values are the mean + SEM. *p<0.05, ***p<0.001 vs. WT group 
(genotype effect). #p<0.05, ##p<0.01 vs. VEH of same genotype (treatment 
effect). $ (main effect of genotype). (2-way ANOVA followed by 
Bonferroni’s post-hoc analysis). 
 
Figure 8. Chronic treatment with mirtazapine (MRZ) increases 
monoamine, GABA and adenosine production in the hippocampus 
(HPC) of Mbnl2
NEX-cKO 
mice. Brain metabolites were quantified in WT 
(n=6 per group) and Mbnl2NEX-cKO (n=6 per group) mice. In the mPFC and 
HPC, 10 mg/kg of MRZ significantly reduced the generation of (a,f) 5-
HT/Trp and (b,g) NA/Tyr in WT mice compared to WT group treated with 
vehicle. Moreover, NA and 5-HT generation were reduced in Mbnl2NEX-cKO 
mice treated with vehicle, in mPFC and HPC respectively. In (c) 
GABA/Glu no significant alterations were found in mPFC, while in 
hippocampal homogenates (h) GABA production was increased in 
Mbnl2NEX-cKO mice treated with MRZ 10 mg/kg. In the ratio (d, i) Glu/Gln 
a significant main effect of genotype was found in both areas, showing that 
Mbnl2NEX-cKO mice had lower production of Glu compared to WT group. A 
main effect of genotype was also found in the levels of (e) adenosine within 
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the mPFC, whereas in the HPC (j) adenosine levels were reduced in 
Mbnl2NEX-cKO mice treated with vehicle and the dose of 10 mg/kg of MRZ 
reversed this effect. Data is expressed as metabolic ratios (area of the 
analyte/area of internal standard). Values are the mean + SEM. *p<0.05, 
***p<0.001 vs. WT group (genotype effect). #p<0.05, ##p<0.01 vs. VEH 
of same genotype (treatment effect). $ (main effect of genotype). (2-way 
ANOVA followed by Bonferroni’s post-hoc analysis). 
 
Suppl. Fig. S1. Generation of Tissue-Specific Mbnl2
NEX-cKO
 Mouse Line. 
Two sequential crosses were made: First we outcrossed (shaded in blue) a 
brain-specific Cre transgene (NEX-Cre+/-) mouse strain with homozygous 
Mbnl2 loxP-flanked mice (Mbnl2fl/fl). In the F1 generation, around the 50% 
of the offspring was hemizygous for the Cre transgene and for the loxP-
flanked allele (Cre+/- ; Mbnl2fl/+) and we backcrossed them (shaded in green) 
with the homozygous Mbnl2 loxP-flanked mice (Mbnl2fl/fl). In the N1 
generation, approximately 25% of the progeny was hemizygous for the Cre 
transgene and homozygous for the loxP-flanked allele (Cre+/- ; Mbnl2fl/fl), 
resulting in our conditional knockout mice (Mbnl2NEX-cKO) and around 25% 
was also homozygous for the loxP-flanked allele but was a non-carrier for 
the Cre transgene (Cre-/- ; Mbnl2fl/fl), resulting in our control group (wild-
type mice). To maintain the colony of our experimental groups (shaded in 
orange), we crossed the Mbnl2NEX-cKO mice with the wild-type mice. 
Suppl. Fig. S2. Timeline of experimental procedures following chronic 
treatment with mirtazapine. (a-b) Schematic representation of the 
experimental design for behavioral procedures. (c) Horizontal locomotion 
during 1 hour of male WT mice treated daily during 5 consecutive days 
with vehicle (VEH) or 1, 3, 10 and 30 mg/kg of mirtazapine. ***p<0.001 
vs vehicle (Bonferroni following one-way ANOVA). 
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FIGURE 2. 
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FIGURE 3. 
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FIGURE 5. 
 
 
 
 
 
 
 
 
 
 
RESULTS: ARTICLE 2 
 
 123 
FIGURE 6. 
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TABLE S1. PCR Primers for Mbnl2
NEX-Cre
 Mouse Conditional 
Knockout Generation 
Genotyping conditional Mbnl2 allele 
Forward primer (5'-3') Reverse primer (5'-3') 
Product 
size (bp) 
GTAGGGCTCTCAAGGAGA
GCACTGCATTGAGC AATGTCAAACCAGACCAG
AAATACACCACCATG 
216 
CGCCTTCTATCGCCTTCTT
GACGAGTTCTTCTGAG 
525 
Genotyping NEX-Cre allele 
Forward primer (5'-3') Reverse primer (5'-3') 
Product 
size (bp) 
GAGTCCTGGAATCAGTCTT
TTTC 
AGAATGTGGAGTAGGGT
GAC 
770 
CCGCATAACCAGTGAAAC
AG 
525 
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TABLE S2. List of Antibodies Used in Immunofluorescence 
Procedures. 
 
 
Primary Antibodies Company Reference Dilution 
Iba1 Wako 019-19741 1:500 
NeuN Millipore MAB377 1:200 
BrdU Abcam ab6326 1:200 
DCX 
Santa Cruz 
Biotechnology 
sc-8066 1:200 
Secondary Antibodies Company Reference 
 
Dilution  
Anti-mouse IgG, HRP-
linked 
Cell Signaling 7076 1:10.000 
Alexa Fluor 555 Anti-
Rabbit IgG  
Thermo Scientific A-32794 1:500 
Alexa Fluor 488 Anti-
Mouse IgG  
JacksonImmuno 
Research 
715-545-
150 
1:500 
Alexa Fluor 488 Anti-Ratt 
IgG  
Abcam ab150157 1:500 
Alexa Fluor 555 Anti-Goat 
IgG  
Thermo Scientific A-32816 1:500 
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TABLE S3. List of Mouse RT-PCR Primers Used for Mbnl2
NEX-Cre
 
Gene Expression Analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GenBank 
Accession 
Number 
 
Name 
 
Forward primer 
(5'-3') 
 
Reverse primer 
(5'-3') 
 
NM_007393.5 
 
Beta-actin 
TCCATCATGA
AGTGTGACGT 
GAGCAATGAT
CTTGATCTTCA
T 
NM_008308.4 5-HT1A receptor GATCTCGCTC
ACTTGGCTCA 
ACTCGATGCA
CCTCGATCAC 
NM_172812.3 5-HT2A receptor ATGCAGTCCA
TCAGCAACGA 
AATGTACCGTG
AGAAGGCGG 
NM_008312.4 5-HT2C receptor GCTGGACCGG
TATGTAGCAA 
GCTTTCGTCCC
TCAGTCCAA 
NM_0010996
44.1 
5-HT3 receptor GACTGCTCAG
CCATGGGAAA 
CAGGGTGATG
CTGTAAGCGA 
NM_0013171
26.1 
Histamine H1 
receptor 
CTGTGGCTGC
TATGCCCGTA 
AGAAATCGGA
GGCGGACTCT 
 
NM_007417.4 
alpha 2A 
adrenergic 
receptor 
GCACAACTTT
GGAAGTCCCG 
TTTCCAACTCC
GTCGCTACC 
 
NM_008361.4 
 
interleukin 1 
beta 
GAAGAGCCCA
TCCTCTGTGA
CT 
GTTGTTCATCT
CGGAGCCTGT
AG 
 
NM_011577.2 
transforming 
growth factor 
beta 1 
CCCGAAGCGG
ACTACTATGC 
ATAGATGGCG
TTGTTGCGGT 
RESULTS: ARTICLE 2 
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1. Mbnl2 KO mice as models of CNS-related alterations 
in DM1  
DM1 is classified as a muscular dystrophy, but the development and 
maintenance of brain function are also deeply affected in this disorder. 
RNA-induced toxicity has been proposed as the main pathological 
mechanism involved in DM1. RNAs containing CUGexp repeats are 
retained and accumulated forming ribonuclear foci in the nucleus of cells 
disrupting a subset of binding proteins required for normal adult CNS 
function; the MBNL protein family. Based on previous studies, MBNL2 
was proposed as the main splicing regulator disrupted in the CNS 
responsible for DM-associated abnormalities in the brain (Charizanis et al., 
2012). In that study, it was reported that Mbnl2 KO mice did not exhibit 
muscle pathology, but recapitulated several phenotypes consistent with 
DM1 neuropathophysiology, such as learning and spatial memory deficits, 
decreased synaptic plasticity and impaired hippocampal LTP. More 
recently, these findings were supported by histopathological studies, where 
it was shown that MBNL2 was sequestered in the HPC and the frontal 
cortex in post-mortem DM1 brains (Goodwin et al., 2015). However, there 
is still a lack of evidence regarding the cellular and molecular mechanisms 
that underlie the neuropsychological deficits related to MBNL2 loss of 
function. Moreover, there is no data as to whether theses alterations are 
progressive or sex-dependent. 
Therefore, during this thesis we used two transgenic mouse lines of 
MBNL2 deficiency to investigate the neurobiological substrates involved 
in the behavioural alterations related to DM1 phenotypes, and to find novel 
pharmacological interventions to reverse them. In the first part, we used 
male and female constitutive Mbnl2 KO mice (Article 1).  
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The advantages of this mouse model were two-fold: First, loss of MBNL2 
protein in the entire brain permitted the comprehensive examination of the 
neurobiological and behavioural underpinnings. Second, the lack of 
muscular deficits in these mice allowed testing them in complex 
behavioural paradigms without counfounding motor effects. One of the 
limitations we encountered when working with constitutive Mbnl2 KO 
mice was maintaining high levels of breeding. Indeed, KO mice offspring 
showed significantly lower weights than their WT littermates, and quite a 
few of them died before weaning. This could be because mothers reject 
smaller offspring focusing on those that are more likely to survive or it 
could be due to an extreme hyperactivity followed by enhanced seizure 
susceptibility (<10%), as already described in Mbnl2 KO and DMSXL mice 
(Charizanis et al., 2012). To curtail these difficulties, for the second part of 
this thesis, we developed a new conditional tissue-specific KO mouse 
model, where the Mbnl2 gene was deleted selectively in the glutamatergic 
neurons of the forebrain (Article 2). The reasoning behind the development 
of this model streamed from the fact that most of the neurochemical 
changes found in constitutive Mbnl2 KO mice were observed in the mPFC 
and the HPC, where MBNL2 protein is highly expressed (Charizanis et al., 
2012; Goodwin et al., 2015). In addition, alterations in the glutamatergic 
system had been previously reported in patients with DM1 (Takado et al., 
2015), and in DMSXL mice (Sicot et al., 2017). To generate this mouse 
line, we used the Cre-lox system based on the recombination of a Cre 
recombinase enzyme, in this case the NEX-Cre, with a pair of short target 
sequences called LoxP sequences that floxed the gene of interest, in our 
case the Mbnl2 gene. Therefore, by crossing a mouse that expresses the 
NEX-Cre promoter with a mouse that has floxed the Mbnl2 gene, in a three-
breeding scheme, we obtained our conditional tissue-specific mouse model 
of Mbnl2 KO.  
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2. Relevant phenotypes in Mbnl2 KO mice 
In this thesis we focused mainly on assessing cognitive and affective 
functions. For this purpose, we used different behavioural tests to examine 
long-term memory, emotional working memory and depressive- and 
anxiety- like states in both Mbnl2 KO mouse models. A detailed summary 
of the behavioral tests carried out during this thesis is shown in Table 3.  
 
To verify that Mbnl2 KO mice did not present any motor deficits in our 
hands, we first assessed locomotor activity using both the open field test 
and locomotor activity cages. In the first study, Mbnl2 KO male mice 
displayed higher horizontal locomotion in the open-field tes than their WT 
littermates at 3 months of age, but this effect was attenuated at 5 months of 
age (Article 1). Moreover, KO female mice showed a greater horizontal 
activity than male KO mice, suggesting that female mice may have a greater 
sensitivity to new environments. In the second study, tissue-specific Mbnl2 
KO mice displayed similar levels of horizontal and exploratory activity in 
locomotor cages at 3 and 8 months compared to WT mice (Article 2). Taken 
together, the locomotor activity in both mouse models, excludes the 
presence of a muscular pathology or muscle deficits. Importantly, since our 
studies were conducted in Mbnl2 KO mice with a maximum of 8 months of 
age, we cannot exclude the possibility that loss of MBNL2 expression may 
contribute to skeletal muscle pathology beyond this age. 
 
Cognitive performance was evaluated using the novel object recognition 
test in both KO mouse models. Constitutive KO mice showed progressive 
impairments in long-term memory from 3 to 5 months of age that were more 
profound in male than female mice. Additionally, male constitutive KO 
mice, also exhibited working memory deficits in the active-avoidance task, 
indicating alterations in emotional working memory processing (Article 1). 
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In line with our results, previous studies have described cognitive 
impairment in patients with DM1 (Caso et al., 2014; Fujino et al., 2018; 
Labayru et al., 2019), and also a mild impairment of working memory in 
DMSXL mice was also described in the Morris water maze (Hernandez-
Hernandez et al., 2013). In female KO mice, long-term recognition memory 
was not so prominent as in male KO mice. Interestingly, in the conditional 
KO mice memory deficits were more intense and persisted over time up to 
8 months of age (Article 2). These findings indicate that the tissue-specific 
deletion of Mbnl2 gene in neocortex and HPC is more deleterious in terms 
of memory recognition than the elimination of this gene in the entire brain, 
suggesting differential compensatory mechanisms in both mice models.  
 
Affective alterations, including depression-like behaviour, anxiety-like 
states, and sleep disturbances were evaluated using several different 
paradigms (see Table 3). Both mouse models of MBNL2 deficiency, 
showed a depressive-like phenotype in the forced swim (FST) and tail 
suspension tests (TST) that persisted over time (Article 1 and 2), but female 
KO mice did not show a depression-like state. Previous studies have shown 
depressive-like symptoms in patients with DM1 (Winblad et al., 2010; Van 
der Velden et al., 2019) and signs of anhedonia in DMSXL mice 
(Hernandez-hernandez 2013). 
 
Moreover, since sleep disturbances may contribute to depressive states in 
DM1 patients (Phillips et al., 1998), we evaluated the circadian activity 
patterns in constitutive male Mbnl2 KO mice (Article 1). In agreement with 
the human data, we found that the pattern of circadian activity was 
interrupted in KO mice. They presented less horizontal activity during the 
dark cycle (activity period) with greater exploratory rearings during the 
light cycle (resting period). These results are in line with previous data 
showing an increase in REM sleep propensity in the same the constitutive 
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Mbnl2 KO model (Charizanis et al., 2012) and depressive-like behaviours 
in mouse models with disrupted circadian rhythms (Landgraf et al., 2016). 
Athough increased anxiety is a well-stablish feature in patients with DM1 
(Van del Velden et al., 2019), our models of MBNL2 deficiency failed to 
reproduce this affective disorder, despite using three different tests to 
evaluate anxiety-like state in constitutive KO mice. These results indicate 
that lack of MBNL2 alone is not crucially implicated in anxiety processes. 
In fact, few studies have reproduced anxiety-like behaviour or motivational 
deficits in mouse models of DM1 including DMSXL and Mbnl1 KO mice 
(Hernandez-Hernandez et al., 2013; Matynia et al., 2010). 
 
Taken together, these data revealed that (i) the cognitive and mood 
disturbances associated with the loss of Mbnl2 gene are progressive and 
more prominent in male than female constitutive Mbnl2 KO mice (Article 
1), and that (ii) loss of Mbnl2 gene specificically in the glutamatergic 
neurons of the forebrain is sufficient to induce DM1-related behavioural 
disturbances (Article 2). 
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Table 3. Behavioural tests used during this thesis:
 
.
Behavioural 
Tests
Assessment Description
Brain regions 
involved
Representation
Novel object 
recognition 
(NOR)
Recognition 
learning and 
memory
Based on the innate preference of mice for
novelty. Consists of 3 phases: 1st)
Habituation to the empty maze, 2nd)
familiarization to 2 identical objects placed
in each arm of the maze and 3rd) one of the
objects is replaced by a new one, and the
exploration time with each of the objects is
measured and represented as a
Discrimination Index (DI), where the highest
scores reflect a great memory of recognition.
Perirhinal 
cortex     
Hippocampus
Active-
avoidance task
Emotional 
working memory
Mice are placed in a two-way shuttle box
and learn to avoid an aversive foot shock
(unconditioned stimulus) with the
presentation of a light as a conditioned
stimulus.
Prefrontal 
cortex    
Amygdala        
Dorsal striatum
Forced swim 
test (FST)
Depressive-like 
behaviour
Mice are placed individually in a cylinder
filled with water during 6 minutes. The total
immobility time is measured during the last
4 minutes. Enchanced immobility represent
a state of behavioural despair characteristic
of depression.
Prefrontal 
cortex  
Hippocampus  
Amygdala    
Tail suspension 
test (TST)
Depressive-like 
behaviour
Mice are individually suspended by the tail
with an adhesive tape during 6 minutes. The
total time spent immobile is measured
during the last 4 minutes. Enchanced
immobility represent a state of behavioural
despair characteristic of depression.
Prefrontal 
cortex  
Hippocampus  
Amygdala    
Phecomp 
cages
Circadian 
rhythm
Mice are individually placed in experimental
chambers. Each box registers horizontal
locomotion, rearing activity and resting time.
After an habituation phase of several days,
the parameters of circadian activity are
measured.
-
Light-dark box
Anxiety-like 
behaviour
One compartment is small and dark, while
the otheris larger and illuminated. The total
number of squares crossed and number of
entries in each compartments was
measured. A more anxious mouse will
spend less time in thr brighly zone.
Hippocampus    
Amygdala     
Limbic regions
Open field test
Locomotor 
response  
Anxiety
Mice are placed in a squared brighlty arena
with surrounding walls that prevent escape.
The exploratory behaviour and general
activity is measured by counting the number
of rearings and number of squares crossed
during a 5-min period.
-
Locomotor 
activity
Locomotor 
response
Mice are tested in individual locomotor
boxes equipped with two lines of infrared
beams in low-lighting conditions (20 lux).
Total horizontal activity and the number of
rearings were analyzed during a 30 min-
period.
-
Elevated pluz 
maze (EPM) 
and elevated 
zero maze 
(EZM)
Anxiety-like 
behaviour
Hippocampus    
Amygdala     
Limbic regions
EMP consists of a maze with 4 arms set in
a cross, whereas EZM is comprised of a ring-
shaped runway. Both are elevated 30 cm
above the fround. It has 2 opposite closed
arms (with vertical walls) with 2 open arms
(unprotected and highly illuminated). The
number of entries and time spent in each
arm are measured. A more anxious mouse
will spend less time in open arms. 
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3. Neuronal and glial changes associated to MBNL2 
loss of function 
Previous studies have reported neuropathological changes with neuronal 
loss (Ono et al., 1998a, b; Mizukami et al., 1999), and diffuse brain damage 
(Itoh et al., 2010) in brains of patients with DM1. In addition, cognitive 
deficits and depression have been related to an altered adult hippocampal 
neurogenesis (Cao et al., 2004) and several neuropsychiatric disorders, such 
as Alzheimer's disease, have been associated with a chronic exacerbation 
of microglia (Donzis and Tronson, 2014; Charlton et al., 2018). Thus, we 
evaluated glial alterations and neuronal loss by quantifying brain 
biomarkers of astrocytes (GFAP), microglia activation (Iba1) and neuronal 
specific marker (NeuN) by immunofluorescence techniques in different 
brain structures of Mbnl2 KO mice models.  
Microglia cells are the major resident immune cells in the CNS that play 
dynamic roles in the healthy brain. Microglia can rapidly respond to 
patgological insults like brain trauma or infection by changing their 
morphology from a ramified, inactive state to an amoeboid reactive state. 
Through the secretion of pro- or anti-inflammatory cytokines they induce a 
range of effects that may contribute either to detrimental effects on 
surrounding neurons, or to neuronal protection (Wake et al., 2011; Nayak 
et al., 2014; Stephenson et al., 2018; Subhramanyam et al., 2019) (Figure 
10). Through the release of cytokines and growth factors, microglia play a 
crucial role in the crosstalk among brain cells such as astrocytes with 
neurons, as well as with regulatory immune cells (von Bernhardi et al., 
2016). 
Moreover, during development and neurogenesis, interactions between 
microglia and neurons are fundamental to shape the patterns of neural 
activity circuits (Wake et al., 2011). Hence, neuroinflammation has been 
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described as a complex immune response designed to protect the body from 
pathogens, toxins or injuries, and it has been linked to depression (Jeon and 
Kim, 2016) and cognitive dysfunction (Heneka et al., 2015; Hein and 
O’Banion, 2012).  
 
 
Figure 10. Schematic representation of the different morphology of microglial 
cells. Upon a pathological damage, microglial cells shift from the surveillance 
phenotype to a reactive state. Following a classical activation, M1 phenotype, 
microglial cells expressed pro-inflammatory cytokines, chemokines and 
neurotoxic factor, while in the M2 phenotype, microglia generally produce anti-
inflammatory neuroprotective factors (Adapted from Subhramanyam et al., 2019). 
 
Although the behavioral alterations observed were similar in the two 
models of MBNL2 deficieny, the associated changes in glial and neuronal 
cells differed between them. Firstly, in the constitutive KO mice, we 
observed a greater widespread microgliosis in areas such as the mPFC, HPC 
and striatum at 6 months of age, but no neuronal loss was detected in any 
brain area. On the other hand, tissue-specific KO mice exhibited a restricted 
microgliosis in the DG of HPC, accompanied by neuronal loss and reduced 
neurogenesis. In both mouse models, we found an increased expression of 
IL-1β, indicating that the overexpression of microglia in these brain areas 
was mainly pro-inflammatory. These findings are consistent with abnormal 
DISCUSSION 
 
 143 
upregulation of pro-inflammatory cytokines reported in patients with DM1 
with increased plasma levels of IL-6 and TNF-α (Johansson et al., 2000; 
Mammarella et al., 2002). Interestingly, it was described that hippocampal 
IL-1β overexpression leads to memory impairment in mice (Hein et al., 
2010). Notably, no astrogliosis was detected in any of the two mouse 
models studied, maybe because astrocytes are less sensitive and respond 
later than microglia to moderate pathological changes in the CNS 
(Liddelow et al., 2017). 
  
The changes in glial and neurons observed in the mPFC and HPC in Mbnl2 
KO mice were associated with cognitive impairments and a depressive 
phenotype. The cortex and the HPC are two key structures in the regulation 
of learning, memory, attention and emotion (Meola and Sandone, 2007; 
Winblad et al., 2010; Cabada et al., 2017). In fact, both HPC and perirhinal 
cortex are required in object recognition memory (Cohen et al., 2013), and 
studies in rats have shown that the integrity of the DG is crucial for 
discriminating between familiar and novel objects (Hunsaker et al., 2008). 
Recently, an 11-year longitudinal follow-up study revealed a specific 
cognitive decline in the domains of visuospatial and visual memory in 
patients with DM1 (Labayru et al., 2019). Accordingly, neuroimaging 
studies showed the involvement of frontotemporal cortices and HPC in 
patients with DM1 (Romeo et al., 2010; Minnerop et al., 2011; Caso et al., 
2014), where several genes were found to be mis-regulated in post-mortem 
brains (Sergeant et al., 2001; Jiang et al., 2004; Furuta et al., 2018). 
 
Overall, the loss of MBNL2 in the constitutive mouse model suggests the 
presence of an initial pathological state consisting in a more generalized 
brain inflammation, but no neuronal loss. On the other hand, the 
inflammation together with neuronal loss and reduced neurogenesis 
observed in the conditional KO mice, specifically in the DG of the HPC, 
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indicate that this structure is particularly sensitive to MBNL2 
downregulation. In addition, these data reveal that the MBNL2 loss of 
function in the DG is sufficient to induce cognitive and depressive-like 
symptoms associated with DM1.  
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4. Neurochemical alterations related to MBNL2 loss 
of function 
Few studies have examined neurochemical signalling in DM1 brains. Early 
investigations demonstrated the involvement of dopaminergic and 
serotonergic pathways in DM1 (Ono et al., 1998a, b), and more recent work 
has shown alterations in the glutamatergic system (Takado et al., 2015; 
Sicot et al., 2017). Thus, to gain deeper insight into the neurochemical 
alterations in DM1, we performed studies investigating possible changes in 
several neurotransmitter systems.  
In constitutive KO mice, we focused on the DA and NA system, and on the 
expression of genes related to plasticity since they play an important role in 
cognitive processes and depression (Seamans and Yang, 2004; Roozendaal 
and Hermans, 2017). We first determined the basal extracellular levels of 
DA using in vivo microdialysis. Our results showed an increase in 
extracellular DA levels of KO mice compared to WT littermates. In contrast 
to these results, previous studies in DMSXL mice reported a significant 
reduction in DA in the frontal cortex. The inconsistencies between both 
studies could probably be due to the use of different DM1 mouse models. 
Hence, DMSXL mice display a high content of RNA foci in the 
dopaminergic brain centres (such as substantia nigra) that could contribute 
to the reduction of DA release (Hernandez-Hernandez et al., 2013). In 
addition, we revealed enhanced gene expression of the DA transporter (Dat) 
and of D1 and D2 DA receptors in the mPFC, while no changes were 
observed in the NA transporter (Net) or its precursor (Dbh). The cognitive 
impairment observed in constitutive KO mice could be associated with an 
excessive activation of these receptors due to excessive DA release (Druzin 
et al., 2000; Vijayraghavan et al., 2007; Robbins and Arnsten, 2009). In the 
HPC, no major changes were found, except for an exacerbated increase in 
Dat levels of KO mice. In addition, our electrophysiological studies showed 
DISCUSSION 
 
 146 
an abnormal neuronal network between mPFC and HPC in KO mice that is 
in line with abnormal activity reported in patients with DM1 (Romeo et al., 
2010). More specifically, we found a decrease in spiking activity of the 
mPFC of KO mice, probably due to excessive stimulation of D1 receptors 
(Zahrt et al., 1997; Vijayraghavan et al., 2007). In the analysis of mRNA 
levels related to plasticity, we found a decrease of brain derived 
neurothrophic factor (BDNF) in the mPFC and HPC of KO mice. This 
downregulation could be associated with the cognitive and depressive-like 
alterations observed in KO mice since this gene has been implicated in 
major depression and synaptic plasticity disorders (Krishnan and Nestler, 
2008). 
In the tissue-specific KO mouse model, we also investigated possible 
changes in the DA and NA system using the targeted metabolomics 
approach in brain tissue homogenates. Unfortunately, DA production in 
mPFC and HPC were undetectable. However, the gene expression level of 
the α2A-adrenergic receptor was significantly decreased in the mPFC and 
NA production was also reduced in this brain area. NA has also shown to 
play a powerful role in working memory and attention in the mPFC through 
its actions at α2A-adrenergic receptors (Ramos and Arnsten, 2007). Thus, 
their downregulation could be associated to the cognitive impairment 
observed in KO mice.  
 
Next, we measured 5-HT production in brain homogenates of tissue-
specific KO mice. Our results showed a significant decrease in 5-HT 
production in the HPC of KO mice. Accordingly, loss of 5-HT neurons has 
been reported in DM1 patients (Ono et al., 1998b), and a significant 
decrease of its main metabolite, 5-hydroxyindolacetic acid (5-HIAA) was 
detected in the brainstem of DMSXL mice (Hernandez-Hernandez et al., 
2013). Several gene expression changes were observed for 5-HT receptors. 
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Particularly, 5-HT1A was significantly reduced in the mPFC and HPC of 
KO mice. This receptor is highly expressed in the granule cells of the DG 
and is involved in the regulation of depression, anxiety and memory 
processes (Verdurand and Zimmer, 2017). Altered levels of this receptor 
have been found in patients with depression (Štrac et al., 2016), and could 
be related to the neuronal loss found in the HPC. However, no major 
changes were found in the transcriptional levels of 5-HT2A, 5-HT2C and 5-
HT3 in the mPFC and HPC. Therefore, reduced 5-HT production and 
decreased gene expression of 5HT1A receptors may have contributed to 
depressive-like behaviour observed in tissue-specific KO mice. 
 
Moreover, we found a lower production of Glu in the mPFC and HPC of 
KO mice. A deterioration of the glutamatergic system has been suggested 
in patients with DM1. In particular, high levels of Gln in the frontal cortex, 
and reduced levels of Glu in white matter were observed (Takado et al., 
2015). In addition, the Glu transporter GLT1, is decreased in DMSXL mice, 
and in post-mortem brains of DM1 patients (Sicot et al., 2017). Glutamate 
transporters protect against exacerbated extracellular concentrations and 
protect neurons from excitotoxicity (Kanai and Hediger, 2004; Bellamy, 
2006). Moreover, the excitatory Glu neurons in the HPC are modulated by 
inhibitory gamma-aminobutyric acid (GABA)-releasing interneurons, and 
adenosine is one of the most important neuromodulators in HPC, regulating 
neuronal excitability and synaptic transmission in the CNS (Sperlágh and 
Vizi, 2011). In this respect, we found a significant reduction of adenosine 
levels in the HPC of KO mice, but with no alterations in the GABAergic 
system. GABA is the primary inhibitory neurotransmitter known to 
counterbalance the action of Glu and plays a role in learning and memory 
(Heaney and Kinney, 2016). Whilst inhibitory A1 adenosine receptors are 
highly expressed in the neocortex, HPC, cerebellum and brain stem, 
excitatory A2A adenosine receptors are restricted to the striatum and 
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olfactory bulb (Sebastiao and Ribeiro, 2009). It is generally accepted that 
adenosine acting on A1 receptors reduces excitatory transmission and is 
neuroprotective in brain injuries associated with neuroinflammation or in 
epileptic seizures, highlighting this compound as a potential target for the 
treatment of neurodegenerative diseases (Ribeiro et al., 2003). Hence, 
interactions between GABAergic and adenosinergic systems in regulating 
neuronal excitability in the HPC are of crucial importance, particularly 
under cell-damaging conditions (Saransaari and Oja, 2005). 
 
Given that the H1 receptor antagonist, hydroxyzine reduces inflammatory 
responses and anxiety (Wiley et al., 2015); we measured the gene 
expression of H1 receptor in the mPFC and HPC. The transcriptional levels 
of H1 receptor were significantly higher in the HPC of KO mice. Thus, the 
exacerbated expression of H1 receptors may be associated with microglia 
activation observed in the DG of the HPC, since these receptors contribute 
to the effects of histamine on microglial phagocytosis and neural death 
(Rocha et al., 2016). Brain histamine is crucial for motivation (Torrealba et 
al., 2012), and regulates cognition, attention and inflammation through 
different histamine receptors (Haas et al., 2008). Unfortunately, we could 
not validate the methodology to correctly quantify histamine production or 
its metabolites using the LC-MS/MS technique. Although the 
metabolomics approach is not as accurate as microdialysis, it allowed us to 
examine more comprehensively changes in several neurotransmitters at the 
same time in the same sample. 
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5. Pharmacological interventions  
The second goal of this thesis was to find novel therapeutic approaches to 
alleviate the DM1 symptomatology related to the CNS. For this purpose, 
we selected two compounds: the psychostimulant methylphenidate, and the 
atypical antidepressant mirtazapine, since they showed anti-DM1 activity 
in screening assays using a Drosophila model of DM1 (Articles 1 and 2), 
and are relevant for DM1 patients, acting on DA and 5-HT 
neurotransmission, which is deregulated in this population. However, these 
compounds induce their effects through different mechanisms of action. 
The psychostimulant methylphenidate blocks DA and NA transporters, 
inhibiting presynaptic reuptake resulting in an increased concentration of 
both neurotransmitter levels at synapses (Volkow et al., 1998; Hannestad et 
al., 2010). On the other hand, mirtazapine has a more complex mechanism 
of action. It is an atypical antidepressant known as a NA and 5-HT specific 
antidepressant (NaSSA). It enhances noradrenergic transmission via 
blockade of α2A-adrenergic receptors, antagonises the 5-HT2A, 5-HT2C and 
5-HT3 serotonergic receptors, as well as the H1 histamine receptor, and 
activates the 5-HT1A receptor (Anttila and Leinonen, 2001).  
 
Both of these drugs were administered chronically in mice, with one daily 
treatment during 21 days. The doses of methylphenidate (1 and 3 mg/kg) 
and mirtazapine (3 and 10 mg/kg) used in our work were carefully chosen 
in pilot studies so that they did not produce detrimental locomotor effects. 
Indeed, methylphenidate induces hyperlocomotion in rodents (Gaytan et 
al., 1997), and mirtazapine has sedative effects in humans (Anttila and 
Leinoen, 2001). Thus, our behavioural studies demonstrated that low doses 
of methylphenidate in the constitutive Mbnl2 KO model and mirtazapine in 
the tissue-specific Mbnl2NEX-CRE KO model reversed the cognitive 
impairment and depression-like behaviour, without affecting the locomotor 
DISCUSSION 
 
 150 
response or anxiety behaviours. Preclinical studies have reported 
contradicting results with long-term administration of methylphenidate on 
cognition with some showing improvement (Veetil and Mukkadan, 2011; 
Carmack et al., 2014a, b; Haleem et al., 2015; Salman et al., 2019), while 
others show impairments in memory (Scherer et al., 2010). Our data are in 
line with evidence of the efficacy of methylphenidate in the treatment of 
depressive symptoms, fatigue and apathy in humans (Hardy, 2009; 
Lavretsky et al., 2015; Mclntyre et al., 2017; Delsalle et al., 2018). Hence, 
methylphenidate is widely used in the clinic to treat attention/hyperactivity 
disorder (ADHD) (Greydanus et al., 2007; Takon et al., 2011; Simon et al., 
2015), and as an off-label adjunct in major depression (Candy et al., 2008; 
Ravindran et al., 2008). The use of stimulants to treat daytime sleepiness in 
DM1 patients has already been described with methylphenidate (Miyamoto 
et al., 2002; Puymirat et al., 2012), and modafinil (MacDonald et al., 2002; 
Orlikowski et al., 2009), but there are no available data on the effects of 
methylphenidate on cognition or depression in these patients. On the other 
hand, our data agree with the findings that mirtazapine is effective in 
patients with moderate to severe depression (Gorman, 1999; Alam et al., 
2013). Moreover, preclinical studies suggest that mirtazapine may possess 
specific pro-cognitive properties (Nowakowska et al., 1999; Borkowska et 
al., 2007; Rogóz, 2013), and it is used as an adjuvant therapy for cognitive 
impairment in schizophrenic patients (Cho et al., 2011; Stenberg et al., 
2013). However, no studies have been conducted in DM1 patients with this 
compound. 
 
The behavioural impairment observed in our models of MBNL2 deficiency 
were associated with increased microgliosis in the mPFC, HPC and 
striatum in the case of a constitutive deletion, and microgliosis, neuronal 
loss and decreased neurogenesis in the DG in the case of the tissue-specific 
deletion. Increasing data indicate that enhanced oxidative stress and chronic 
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neuroinflammation are common pathological mechanisms underlying 
neurodegenerative diseases (Mosley et al., 2006; Agostinho et al., 2010; 
Buendia et al., 2016), and increased serum levels of IL-6 have been found 
in patients with DM1 (Johansson et al., 2000). In constitutive KO mice, 
methylphenidate attenuated microglia overexpression and the pro-
inflammatory cytokine IL-1β in the mPFC of KO mice. Consistent with 
these data, chronic methylphenidate administration decreases serum levels 
of other pro-inflammatory cytokines in a rat model with depression and 
cognitive deficits (Aga-Mizrachi et al., 2014). Similarly, in conditional KO 
mice mirtazapine reduced the pro-inflammatory microglial exacerbation in 
the HPC, reducing the transcriptional levels of IL-1β. In agreement, chronic 
treatment with mirtazapine has been shown to reduce plasma levels of pro-
inflammatory markers in patients with major depressive disorder (Tulner et 
al., 2011). In addition, the beneficial effects of mirtazapine on inflammatory 
response, where accompanied by increased neurogenesis and reduced 
neuronal loss in the DG of the HPC. In accordance, hippocampal plasticity 
induced by chronic antidepressant treatment occurs through an increase in 
adult hippocampal neurogenesis (Malberg et al., 2000), and it has been 
reported that these cellular adaptations play an important role in the 
behavioural effects of antidepressants (Santarelli et al., 2003).   
 
Taken together, our results reveal that both methylphenidate and 
mirtazapine may restore neuroglial communications in the mPFC and HPC 
that have been compromised by the loss of MBNL2, and that this effect 
attenuates the depressive-like state and cognitive deficits observed in KO 
mice.  
To gain deeper insight into de mechanisms of action of these two 
compounds, we performed neurochemical and gene expression studies in 
the constitutive Mbnl2 KO model and in the tissue-specific Mbnl2NEX-CRE KO 
model. Our findings indicated that chronic treatment with methylphenidate 
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increased D1 receptor gene expression in the mPFC, while it attenuated the 
enhancement in Dat and D2 receptors in constitutive KO mice. 
Accordingly, some studies have associated the therapeutic effects of 
methylphenidate in ADHD with the stimulation of prefrontal D1 receptors 
(Arnsten and Dudley, 2005). In the HPC, Dat transcription levels were 
attenuated in KO mice, while chronic methylphenidate had subtle effects 
on D1 and D2 receptors. More recent evidence has revealed that 
methylphenidate increases PFC cell activity through D2 receptors (de la 
Peña et al., 2018). It is known that D2 receptors play a critical role in the 
behavioural effects of psychostimulants (Self and Nestler, 1995; Volkow et 
al., 2007). In addition, we found that the downregulation of Brain-derived 
neurotrophic factor (Bdnf) gene expression observed in constitutive KO 
mice in the mPFC and HPC was reversed. Our findings are consistent with 
previous results showing that methylphenidate increased hippocampal 
BDNF protein and reversed spatial memory deficits in a rat model of 
ADHD (Jichao et al., 2017). BDNF in serum is considered a good marker 
for lesions in the CNS since they can easily cross the blood brain barrier. 
Indeed, lower levels of BDNF expression may contribute to the 
pathogenesis of several disorders related to cognitive deficits and 
depression such as Huntington’s disease or Alzheime’s disease (Lu et al., 
2014). Notably, methylphenidate increased nuclear factor erythroid 2-
related factor 2 (Nrf2) mRNA levels specifically in the HPC of KO mice. 
NRF2 is a key marker of antioxidant responses (Perez-Leal et al., 2017), 
and a depressive-like state has been reported in Nrf2 KO mice (Yao et al., 
2016).  
 
Our gene expression studies using mirtazapine revealed an increase in the 
expression of the 5-HT1A receptor and a decrease in the levels of the 
histamine H1 receptor in tissue-specific KO mice. Both of these receptors 
are crucially involved in depression, anxiety and memory processes 
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(Verdurand and Zimmer, 2017). While 5-HT1A receptors are critical for the 
behavioral and neurogenic effects of the antidepressants (Samuels et al., 
2015), H1 receptors are associated to inflammatory responses (Rocha et al., 
2016). Thus, the neuroprotective and anti-inflammatory effects of 
mirtazapine observed in the DG of KO mice could be attributed to its action 
on 5-HT1A receptor and H1 receptors, respectively. We also determined the 
effects of chronic mirtazapine treatment on brain neurotransmitters and 
their metabolites related with depression and cognitive functions. Major 
changes were found in the HPC, where mirtazapine increased the 5-HT and 
NA production (Anttila and Leinonen, 2001), as expected. Interestingly, 
mirtazapine increased the production of GABA and adenosine 
neurotransmitters in the HPC of KO mice. Accordingly, previous studies 
have shown that mirtazapine increases GABA and reduces Glu 
concentrations in nucleus accumbens homogenates in a rat model of chronic 
mild stress (Kamal et al., 2013), suggesting a potential GABAergic target 
for mirtazapine in the treatment of depressive disorders. Furthermore, 
adenosine is one of the most important neuromodulators in HPC, regulating 
neuronal excitability and synaptic transmission in the CNS (Sperlágh and 
Vizi, 2011). While no evidence is currently available as to the effects of 
mirtazapine on adenosine neurotransmission, our data suggests that this 
compound may be increasing adenosine in the HPC to modulate neuronal 
and glial stability. Indeed, adenosine acting on A1 receptors reduces 
excitatory transmission, and is neuroprotective in brain injuries (Ribeiro et 
al., 2003). 
 
Altogether, our findings provide evidence that methylphenidate and 
mirtazapine could be a novel therapeutic treatment to counteract the 
neurodegenerative process, and the cognitive and mood alterations related 
to DM1 by complementary mechanisms. Thus, the beneficial effects of 
methylphenidate on behavioural alterations observed in mice with 
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constitutive MBNL2 loss-of-function may be attributed to reducing 
widespread microglia overexpression and antioxidant responses by 
increasing Bdnf and reducing NRf2 levels, and by normalizing D2 receptor 
and increasing D1 receptor gene expression in the mPFC. On the other 
hand, mirtazapine attenuates the pathological behavioural manifestations 
due to loss of MBNL2 protein in the DG by reducing neuroinflammation 
and neuronal loss, and probably also by increasing neurogenesis in this 
brain area through 5HT1A and H1 receptors. Notably, we demonstrated for 
the first time that mirtazapine’s favourable effects may involve decreasing 
neuronal excitation through a mechanism of action involving GABA and 
adenosine neurotransmission.  
 
Despite these positive results obtained with both drugs in animal models, 
potential disadvantageous side effects must be highlighted and reviewed 
before it can be approved for use in DM1 patients. Thus, in the case of 
methylphenidate, it has been reported that it may increase the risk to 
develop a cardiac pathology in vulnerable individuals (Roose and 
Rutherford, 2015), and it may induce addictive properties depending on the 
dose and the route of administration employed (Morton and Stockton, 
2000). Similarly, mirtazapine induces sedation, which would be counter 
beneficial for DM1 patients who suffer from excessive day time sleepiness.   
However, this drug has been shown to be effective and safe during long-
term use (Anttila and Leinonen, 2001), and it is usually administered at 
night when somnolence would be less of an issue for DM1 patients.
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The findings obtained in the present thesis revealed that: 
1. Both mouse models of MBNL2 deficiency (constitutive Mbnl2 KO and the 
Mbnl2NEX-CRE KO) resulted in cognitive deficits and depressive-like 
behavior, which were progressive and persisted up to 8 months of age, and 
they were more prominent in male than in female mice, recapitulating the 
neuropsychological disturbances observed in patients with DM1. 
 
2. Behavioral alterations in constitutive Mbnl2 KO mice were associated with 
a deregulated DA system in the mPFC, including increased DA levels, and 
increased transcriptional levels of Dat, and D1 and D2 receptors, and with 
a pro-inflammatory process in the mPFC and HPC. 
 
3. Chronic methylphenidate treatment attenuated cognitive and depressive 
symptoms in constitutive Mbnl2 KO by reducing overexpression of 
microglia and normalizing gene expression of Dat and D2 receptors in the 
mPFC, and by increasing plasticity and reducing oxidative stress 
biomarkers in HPC. 
 
4. Behavioral abnormalities in tissue-specific Mbnl2NEX-CRE KO mice were 
associated with neuronal and glial alterations specifically in the DG of the 
HPC, as well as altered neurotransmitter levels in the HPC. 
 
5. Chronic treatment with mirtazapine reverses the behavioral deficits in 
Mbnl2NEX-CRE KO mice by reducing microglia and neuronal loss in the DG 
of the HPC, by normalizing the gene expression of 5-HT1AR and H1R 
receptors in the HPC, and by modulating the balance of monoamine, GABA 
and adenosine levels in the HPC. 
 
6. Methylphenidate and mirtazapine could be novel potential avenues for the 
treatment of the neuropsychological disturbances observed in patients with 
DM1. 
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